U.S. patent application number 11/556208 was filed with the patent office on 2011-02-24 for diagnostic and therapeutic epitope, and transgenic plant.
This patent application is currently assigned to ISIS INNOVATION LIMITED. Invention is credited to Robert Anderson, Adrian Hill, Derek Jewell.
Application Number | 20110044912 11/556208 |
Document ID | / |
Family ID | 10861989 |
Filed Date | 2011-02-24 |
United States Patent
Application |
20110044912 |
Kind Code |
A2 |
Anderson; Robert ; et
al. |
February 24, 2011 |
Diagnostic And Therapeutic Epitope, And Transgenic Plant
Abstract
A peptide analogue which is not more than 50 amino acids in
length, and which is capable of being recognized by a T cell
receptor that recognizes an epitope comprising sequence
.sup.62PQPELPY.sup.68 (SEQ ID NO:1), and fusion proteins,
pharmaceutical compositions, and kits comprising the same, are
provided herewith. Also provided are methods of diagnosing coeliac
disease, or susceptibility to coeliac disease, in an individual
comprising contacting a sample from the individual with a peptide
analogue and determining in vitro whether T cells in the sample
recognize the peptide analogue.
Inventors: |
Anderson; Robert; (Oxford,
GB) ; Hill; Adrian; (Oxford, GB) ; Jewell;
Derek; (Oxford, GB) |
Correspondence
Address: |
Pepper Hamilton LLP
400 Berwyn Park
899 Cassatt Road
Berwyn
PA
19312-1183
UNITED STATES
610.640.7800
610.640.7835
|
Assignee: |
ISIS INNOVATION LIMITED
Ewert House, Ewert Place Summertown
Oxford
GB
OX2 7SG
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20090269285 A1 |
October 29, 2009 |
|
|
Family ID: |
10861989 |
Appl. No.: |
11/556208 |
Filed: |
November 3, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10/089,700 |
Dec 5, 2006 |
7144569 |
|
|
PCT/GB00/03760 |
Oct 2, 2000 |
|
|
|
11556208 |
Nov 3, 2006 |
|
|
|
Current U.S.
Class: |
424/9.81 ;
435/29; 436/501; 514/13.2; 530/326; 530/329; 530/330; 530/402;
800/278 |
Current CPC
Class: |
G01N 2333/9108 20130101;
A61P 43/00 20180101; A61K 49/0006 20130101; G01N 33/6863 20130101;
G01N 33/6878 20130101; G01N 33/505 20130101; C12N 15/8258 20130101;
Y10S 435/975 20130101; A61P 1/00 20180101; A61P 37/08 20180101;
A61P 37/06 20180101; C12N 15/8257 20130101; C07K 14/415 20130101;
G01N 33/564 20130101; G01N 33/6854 20130101 |
Class at
Publication: |
424/009.81 ;
530/329; 530/326; 530/402; 435/029; 436/501; 530/330; 514/013.2;
800/278 |
International
Class: |
A61K 49/00 20060101
A61K049/00; C07K 7/06 20060101 C07K007/06; C07K 7/08 20060101
C07K007/08; A61K 38/08 20060101 A61K038/08; A61K 38/10 20060101
A61K038/10; C07K 14/00 20060101 C07K014/00; A61K 38/16 20060101
A61K038/16; C12Q 1/02 20060101 C12Q001/02; G01N 33/53 20060101
G01N033/53; A61P 1/00 20060101 A61P001/00; A01H 5/00 20060101
A01H005/00 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 1, 1999 |
GB |
9923306.6 |
Claims
1.-59. (canceled)
60. A peptide analogue which is not more than 50 amino acids in
length, and which is capable of being recognised by a T cell
receptor or an antibody that recognises an epitope comprising
sequence .sup.62PQPELPY.sup.68 or
.sup.57QLQPFPQPELPYPQPQS.sup.73.
61. A peptide analogue according to claim 60 which comprises one or
more amino acid substitutions in the amino acid sequence
.sup.62PQPELPY.sup.68 or .sup.57QLQPFPQPELPYPQPQS.sup.73.
62. A peptide analogue according to claim 61 wherein the glutamic
acid residue at position 65 is substituted by an asparagine,
aspartic acid, alanine, cysteine, serine, valine or threonine
residue.
63. A peptide analogue according to claim 61 which comprises the
amino acid substitution S63, I63, M63, V62, or V68.
64. A peptide analogue according to claim 61 which comprises the
amino acid substitution Y62, W62, L63, I62, W68, F62, V63, H63,
F63, T62, T63, M66, S62, M62, A63, L62, I68, S67, Q62, F68, N65,
A62, A68, P66, S68, Y63, E63, T64, T67, or D63.
65. A peptide analogue according to claim 61 which comprises the
amino acid substitution 65T, 67M, 64W, or 67W.
66. A peptide analogue according to claim 60 which comprises the
amino acid substitution Y61 or Y70.
67. A peptide analogue according to claim 60 which comprises the
amino substitution W70, K57, Y59, A57, S70, K58, W59, A73, I59,
G59, A58, W60, A59, K72, S59, K73, A70, Y60, A72, K59, I60, G70,
E70, S60, P59, K71, I70, I61, E59, P57, Q58, L59, P73, or L73.
68. A peptide analogue according to claim 60 which comprises the
amino acid substitution W61, A60, G60, A71, Q60, K70, H61, S69,
P70, L61, S61, T61, T69, K60, M61, P61, Q61, G61, N61, I69, V61,
D61, E60, A61, R61, N69, or Y69.
69. A peptide analogue according to claim 60 which comprises a
non-natural amino acid.
70. A composition comprising one or more of the peptide analogues
according to claim 60.
71. A pharmaceutical composition comprising a peptide analogue
according to claim 60 and a pharmaceutically acceptable carrier or
diluent.
72. A fusion protein comprising a peptide analogue according to
claim 60 and other gliadin or non-gliadin sequence.
73. A fusion protein according to claim 72 which comprises a
non-natural amino acid.
74. A composition comprising one or more of the fusion proteins
according to claim 72.
75. A pharmaceutical composition comprising a fusion protein
according to claim 72 and a pharmaceutically acceptable carrier or
diluent.
76. A method of diagnosing coeliac disease, or susceptibility to
coeliac disease, in an individual comprising: a) contacting a
sample from the individual with a peptide analogue according to
claim 60; and b) determining in vitro whether T cells in the sample
recognise the peptide analogue, wherein recognition by the T cells
indicates that the individual has or is susceptible to coeliac
disease.
77. A method according to claim 76 wherein the sample is a blood
sample.
78. A method of diagnosing coeliac disease, or susceptibility to
coeliac disease, in an individual comprising: a) contacting a
sample from the individual with a fusion protein according to claim
72; and b) determining in vitro whether T cells in the sample
recognise the fusion protein, wherein recognition by the T cells
indicates that the individual has or is susceptible to coeliac
disease.
79. A method according to claim 78 wherein the sample is a blood
sample.
80. A method of diagnosing coeliac disease, or susceptibility to
coeliac disease, in an individual comprising: a) administering a
peptide analogue according to claim 60 to the skin of the
individual; and b) detecting the presence of inflammation at the
site of administration, wherein detection of inflammation indicates
that the T cells of the individual recognise the peptide
analogue.
81. A method of diagnosing coeliac disease, or susceptibility to
coeliac disease, in an individual comprising: a) administering a
fusion protein according to claim 72 to the skin of the individual;
and b) detecting the presence of inflammation at the site of
administration, wherein detection of inflammation indicates that
the T cells of the individual recognise the fusion protein.
82. A method of diagnosing coeliac disease, or susceptibility to
coeliac disease in an individual comprising: a) contacting a sample
from the individual with a peptide comprising the amino acid
sequence .sup.62PQPELPY.sup.68 or .sup.57QLQPFPQPELPYPQPQS.sup.73
or a peptide analogue according to claim 60; and b) determining the
presence of an antibody that binds to the peptide or peptide
analogue, wherein the presence of the antibody indicates that the
individual has, or is susceptible to, coeliac disease.
83. A method of diagnosing coeliac disease, or susceptibility to
coeliac disease in an individual comprising: a) contacting a sample
from the individual with a peptide comprising the amino acid
sequence .sup.62PQPELPY.sup.68 or .sup.57QLQPFPQPELPYPQPQS.sup.73
or a fusion protein according to claim 72; and b) determining the
presence of an antibody that binds to the peptide or fusion
protein, wherein the presence of the antibody indicates that the
individual has, or is susceptible to, coeliac disease.
84. A method for identifying an analogue of a peptide comprising
the amino acid sequence .sup.62PQPELPY.sup.68 or
.sup.57QLQPFPQPELPYPQPQS.sup.73 comprising: determining whether a
candidate substance is recognised by a T cell receptor or an
antibody that recognises the peptide, wherein recognition of the
substance indicates that the substance is an analogue.
85. A method of preventing or treating coeliac disease in an
individual comprising administering a peptide analogue according to
claim 60 to the individual.
86. A method of preventing or treating coeliac disease in an
individual comprising administering a fusion protein according to
claim 72 to the individual.
87. A kit comprising: a peptide analogue according to claim 60; and
a means to detect the recognition of the peptide analogue by the T
cell.
88. A kit comprising: a fusion protein according to claim 72; and a
means to detect the recognition of the fusion peptide by the T
cell.
89. A kit comprising: a peptide comprising the amino acid sequence
.sup.62PQPELPY.sup.68 or .sup.57QLQPFPQPELPYPQPQS.sup.73 or a
peptide analogue according to claim 60; and a means to detect
binding of an antibody that binds to the peptide or peptide
analogue.
90. A kit comprising: a peptide comprising the amino acid sequence
.sup.62PQPELPY.sup.68 or .sup.57QLQPFPQPELPYPQPQS.sup.73 or a
fusion protein according to claim 72; and a means to detect binding
of an antibody that binds to the peptide or fusion protein.
91. A peptide analogue which is not more than 50 amino acids in
length, and which is capable of being recognised by a T cell
receptor or an antibody that recognises an epitope comprising
sequence .sup.63QPELP.sup.67.
92. A peptide analogue which is not more than 50 amino acids in
length, and which is capable of being recognised by a T cell
receptor or an antibody that recognises an epitope comprising
sequence .sup.64PELPY.sup.68.
Description
[0001] The invention relates to the diagnosis and therapy of
coeliac disease, and to a gliadin protein which does not cause
coeliac disease.
[0002] An immune reaction to gliadin (a component of gluten) in the
diet causes coeliac disease. It is known that immune responses in
the intestinal tissue preferentially respond to gliadin which has
been modified by an intestinal transglutaminase. Coeliac disease is
diagnosed by detection of anti-endomysial antibodies, but this
requires confirmation by the finding of a lymphocytic inflammation
in intestinal biopsies. The taking of such a biopsy is inconvenient
for the patient.
[0003] Investigators have previously assumed that only intestinal T
cell responses provide an accurate indication of the immune
response against gliadins. Therefore they have concentrated on the
investigation of T cell responses in intestinal tissue.sup.1.
Gliadin epitopes which require transglutaminase modification
(before they are recognised by the immune system) are
known.sup.2.
[0004] The inventors have found the immunodominant T cell epitope
recognised by the immune system in coeliac disease, and have shown
that this is recognised by T cells in the peripheral blood of
individuals with coeliac disease. Such T cells were found to be
present at high enough frequencies to be detectable without
restimulation (i.e. a `fresh response` detection system could be
used). The epitope was identified using a non-T cell cloning based
method which provided a more accurate reflection of the epitopes
being recognised. The immunodominant epitope requires
transglutaminase modification (causing substitution of a particular
glutamine to glutamate) before immune system recognition.
[0005] Based on this work the inventors have developed a test which
can be used to diagnose coeliac disease at an early stage. The test
may be carried out on a sample from peripheral blood and therefore
an intestinal biopsy is not required. The test is more sensitive
than the antibody tests which are currently being used.
[0006] The invention thus provides a method of diagnosing coeliac
disease, or susceptibility to coeliac disease, in an individual
comprising:
[0007] (a) contacting a sample from the host with an agent selected
from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or
2, or an equivalent sequence from a naturally occurring homologue
of the gliadin represented by SEQ ID NO:3, (ii) an epitope
comprising sequence comprising: SEQ ID NO: 1, or an equivalent
sequence from a naturally occurring homologue of the gliadin
represented by SEQ ID NO:3, which epitope is an isolated
oligopeptide derived from a gliadin protein, (iii) an analogue of
(i) or (ii) which is capable of being recognised by a T cell
receptor that recognises (i) or (ii), which in the case of a
peptide analogue is not more than 50 amino acids in length, or (iv)
a product comprising two or more agents as defined in (i), (ii) or
(iii), and (b) determining in vitro whether T cells in the sample
recognise the agent, recognition by the T cells indicating that the
individual has, or is susceptible to, coeliac disease.
[0008] The invention also provides use of the agent for the
preparation of a diagnostic means for use in a method of diagnosing
coeliac disease, or susceptibility to coeliac disease, in an
individual, said method comprising determining whether T cells of
the individual recognise the agent, recognition by the T cells
indicating that the individual has, or is susceptible to, coeliac
disease.
[0009] The finding of an immunodominant epitope which is modified
by transglutaminase also allows diagnosis of coeliac disease based
on determining whether other types of immune response to this
epitope are present. Thus the invention also provides a method of
diagnosing coeliac disease, or susceptibility to coeliac disease,
in an individual comprising determining the presence of an antibody
that binds to the epitope in a sample from the individual, the
presence of the antibody indicating that the individual has, or is
susceptible to, coeliac disease.
[0010] The invention additionally provides the agent, optionally in
association with a carrier, for use in a method of treating or
preventing coeliac disease by tolerising T cells which recognise
the agent. Also provided is an antagonist of a T cell which has a T
cell receptor that recognises (i) or (ii), optionally in
association with a carrier, for use in a method of treating or
preventing coeliac disease by antagonising such T cells.
Additionally provided is the agent or an analogue that binds an
antibody (that binds the agent) for use in a method of treating or
preventing coeliac disease in an individual by tolerising the
individual to prevent the production of such an antibody.
[0011] The invention provides a method of determining whether a
composition is capable of causing coeliac disease comprising
determining whether a protein capable of being modified by a
transglutaminase to an oligopeptide sequence as defined above is
present in the composition, the presence of the protein indicating
that the composition is capable of causing coeliac disease.
[0012] The invention also provides a mutant gliadin protein whose
wild-type sequence can be modified by a transglutaminase to a
sequence that comprises an epitope comprising sequence as defined
above, but which mutant gliadin protein has been modified in such a
way that it does not contain sequence which can be modified by a
transglutaminase to a sequence that comprises such an epitope
comprising sequence; or a fragment of such a mutant gliadin protein
which is at least 15 amino acids long and which comprises sequence
which has been modified in said way.
[0013] The invention also provides a protein that comprises a
sequence which is able to bind to a T cell receptor, which T cell
receptor recognises the agent, and which sequence is able to cause
antagonism of a T cell that carries such a T cell receptor.
[0014] Additionally the invention provides a food that comprises
the proteins defined above.
[0015] The invention is illustrated by the accompanying drawings in
which:
[0016] FIG. 1 shows freshly isolated PBMC (peripheral blood
mononuclear cell) IFN.gamma. ELISPOT responses (vertical axis shows
spot forming cells per 10.sup.6 PBMC) to transglutaminase
(tTG)-treated and untreated peptide pool 3 (each peptide 10
.mu.g/ml) including five overlapping 15mers spanning A-gliadin
51-85 (see Table 1) and a-chymotrypsin-digested gliadin (40
.mu.g/ml) in coeliac disease Subject 1, initially in remission
following a gluten free diet then challenged with 200 g bread daily
for three days from day 1 (a). PBMC IFN.gamma. ELISPOT responses by
Subject 2 to tTG-treated A-gliadin peptide pools 1-10 spanning the
complete A-gliadin protein during ten day bread challenge (b). The
horizontal axis shows days after commencing bread.
[0017] FIG. 2 shows PBMC IFN.gamma. ELISPOT responses to
tTG-treated peptide pool 3 (spanning A-gliadin 51-85) in 7
individual coeliac disease subjects (vertical axis shows spot
forming cells per 10.sup.6 PBMC), initially in remission on gluten
free diet, challenged with bread for three days (days 1 to 3). The
horizontal axis shows days after commencing bread. (a). PBMC IFNg
Elispot responses to tTG-treated overlapping 15mer peptides
included in pool 3; bars represent the mean (.+-.SEM) response to
individual peptides (10 .mu.g/ml) in 6 Coeliac disease subjects on
day 6 or 7 (b). (In individual subjects, ELISPOT responses to
peptides were calculated as a % of response elicited by peptide
12--as shown by the vertical axis.)
[0018] FIG. 3 shows PBMC IFN.gamma. ELISPOT responses to
tTG-treated truncations of A-gliadin 56-75 (0.1 .mu.M). Bars
represent the mean (.+-.SEM) in 5 Coeliac disease subjects. (In
individual subjects, responses were calculated as the % of the
maximal response elicited by any of the peptides tested.)
[0019] FIG. 4 shows how the minimal structure of the dominant
A-gliadin epitope was mapped using tTG-treated 7-17mer A-gliadin
peptides (0.1 .mu.M) including the sequence, PQPQLPY (A-gliadin
62-68) (a), and the same peptides without tTG treatment but with
the substitution Q.fwdarw.E65 (b). Each line represents PBMC IFNg
ELISPOT responses in each of three Coeliac disease subjects on day
6 or 7 after bread was ingested on days 1-3. (In individual
subjects, ELISPOT responses were calculated as a % of the response
elicited by the 17mer, A-gliadin 57-73.)
[0020] FIG. 5 shows the amino acids which were deamidated by tTG.
A-gliadin 56-75 (LQLQPFPQPQLPYPQPQSFP) (0.1 .mu.M) was incubated
with tTG (50 .mu.g/ml) at 37.degree. C. for 2 hours. A single
product was identified and purified by reverse phase HPLC. Amino
acid analysis allowed % deamidation (Q.fwdarw.E) of each Gln
residue in A-gliadin 56-75 attributable to tTG to be calculated
(vertical axis).
[0021] FIG. 6 shows the effect of substituting Q.fwdarw.E in
A-gliadin 57-73 at other positions in addition to Q65 using the
17mers: QLQPFPQPELPYPQPES (E57,65), QLQPFPQPELPYPQPES (E65,72),
ELQPFPQPELPYPQPES (E57, 65, 72), and QLQPFPQPELPYPQPQS (E65) in
three Coeliac disease subjects on day 6 or 7 after bread was
ingested on days 1-3. Vertical axis shows % of the E65
response.
[0022] FIG. 7 shows that tTG treated A-gliadin 56-75 (0.1 .mu.M)
elicited IFN-g ELISPOT responses in (a) CD4 and CD8 magnetic bead
depleted PBMC. (Bars represent CD4 depleted PBMC responses as a %
of CD8 depleted PBMC responses; spot forming cells per million CD8
depleted PBMC were: Subject 4: 29, and Subject 6: 535). (b) PBMC
IFN.gamma. ELISPOT responses (spot forming cells/million PBMC)
after incubation with monoclonal antibodies to HLA-DR (L243), -DQ
(L2) and -DP (B7.21) (10 .mu.g/ml) 1 h prior to tTG-treated 56-75
(0.1 .mu.M) in two coeliac disease subjects homozygous for HLA-DQ
a1*0501, b1*0201.
[0023] FIG. 8 shows the effect of substituting Glu at position 65
for other amino acids in the immunodominant epitope. The vertical
axis shows the % response in the 3 subjects in relation to the
immunodominant epitope.
[0024] FIG. 9 shows the immunoreactivity of naturally occurring
gliadin peptides (measuring responses from 3 subjects) which
contain the sequence PQLPY with (shaded) and without (clear)
transglutaminase treatment.
[0025] FIG. 10 shows CD8, CD4, .beta..sub.7, and
.alpha..sup.E-specific immunomagnetic bead depletion of peripheral
blood mononuclear cells from two coeliac subjects 6 days after
commencing gluten challenge followed by interferon gamma ELISpot.
A-gliadin 57-73 QE65 (25 mcg/ml), tTG-treated chymotrypsin-digested
gliadin (100 mcg/ml) or PPD (10 mcg/ml) were used as antigen.
[0026] FIG. 11 shows the optimal T cell epitope length.
[0027] FIG. 12 shows a comparison of A-gliadin 57-73 QE65 with
other peptides in a dose response study.
[0028] FIG. 13 shows a comparison of gliadin and A-gliadin 57-73
QE65 specific responses.
[0029] FIG. 14 shows the bioactivity of gliadin polymorphisms in
coeliac subjects.
[0030] FIGS. 15 and 16 show the defining of the core epitope
sequence.
[0031] FIGS. 17 to 27 show the agonist activity of A-gliadin 57-73
QE65 variants.
[0032] FIG. 28 shows responses in different patient groups.
DETAILED DESCRIPTION OF THE INVENTION
[0033] The term `coeliac disease` encompasses a spectrum of
conditions caused by varying degrees of gluten sensitivity,
including a severe form characterised by a flat small intestinal
mucosa (hyperplastic villous atrophy) and other forms characterised
by milder symptoms.
[0034] The individual mentioned above (in the context of diagnosis
or therapy) is human. They may have coeliac disease (symptomatic or
asymptomatic) or be suspected of having it. They may be on a gluten
free diet. They may be in an acute phase response (for example they
may have coeliac disease, but have only ingested gluten in the last
24 hours before which they had been on a gluten free diet for 14 to
28 days).
[0035] The individual may be susceptible to coeliac disease, such
as a genetic susceptibility (determined for example by the
individual having relatives with coeliac disease or possessing
genes which cause predisposition to coeliac disease).
The Agent
[0036] The agent is typically a peptide, for example of length 7 to
50 amino acids, such as 10 to 40, or 15 to 30 amino acids in
length.
[0037] SEQ ID NO: 1 is PQPELPY. SEQ ID NO:2 is QLQPFPQPELPYPQPQS.
SEQ ID NO:3 is shown in Table 1 and is the sequence of a whole
A-gliadin. The glutamate at position 4 of SEQ ID NO:1 (equivalent
to position 9 of SEQ ID NO:2) is generated by transglutaminase
treatment of A-gliadin.
[0038] The agent may be the peptide represented by SEQ ID NO:1 or 2
or an epitope comprising sequence that comprises SEQ ID NO:1 which
is an isolated oligopeptide derived from a gliadin protein; or an
equivalent of these sequences from a naturally occurring gliadin
protein which is a homologue of SEQ ID NO:3. Thus the epitope may
be a derivative of the protein represented by SEQ ID NO:3. Such a
derivative is typically a fragment of the gliadin, or a mutated
derivative of the whole protein or fragment. Therefore the epitope
of the invention does not include this naturally occurring whole
gliadin protein, and does not include other whole naturally
occurring gliadins.
[0039] The epitope may thus be a fragment of A-gliadin (e.g. SEQ ID
NO:3), which comprises the sequence of SEQ ID NO:1, obtainable by
treating (fully or partially) with transglutaminase, i.e. with 1,
2, 3 or more glutamines substituted to glutamates (including the
substitution within SEQ ID NO:1).
[0040] Such fragments may be or may include the sequences
represented by positions 55 to 70, 58 to 73, 61 to 77 of SEQ ID
NO:3 shown in Table 1. Typically such fragments will be recognised
by T cells to at least the same extent that the peptides
represented by SEQ ID NO:1 or 2 are recognised in any of the assays
described herein using samples from coeliac disease patients.
[0041] In the case where the epitope comprises a sequence
equivalent to the above epitopes (including fragments) from another
gliadin protein (e.g. any of the gliadin proteins mentioned herein
or any gliadins which cause coeliac disease), such equivalent
sequences will correspond to a fragment of a gliadin protein
typically treated (partially or fully) with transglutaminase. Such
equivalent peptides can be determined by aligning the sequences of
other gliadin proteins with SEQ ID NO:3 (for example using any of
the programs mentioned herein). Transglutaminase is commercially
available (e.g. Sigma T-5398). Table 4 provides examples of
suitable equivalent sequences.
[0042] The agent which is an analogue is capable of being
recognised by a TCR which recognises (i) or (ii). Therefore
generally when the analogue is added to T cells in the presence of
(i) or (ii), typically also in the presence of an antigen
presenting cell (APC) (such as any of the APCs mentioned herein),
the analogue inhibits the recognition of (i) or (ii), i.e. the
analogue is able to compete with (i) or (ii) in such a system.
[0043] The analogue may be one which is capable of binding the TCR
which recognises (i) or (ii). Such binding can be tested by
standard techniques. Such TCRs can be isolated from T cells which
have been shown to recognise (i) or (ii) (e.g. using the method of
the invention). Demonstration of the binding of the analogue to the
TCRs can then shown by determining whether the TCRs inhibit the
binding of the analogue to a substance that binds the analogue,
e.g. an antibody to the analogue. Typically the analogue is bound
to a class II MHC molecule (e.g. HLA-DQ2) in such an inhibition of
binding assay.
[0044] Typically the analogue inhibits the binding of (i) or (ii)
to a TCR. In this case the amount of (i) or (ii) which can bind the
TCR in the presence of the analogue is decreased. This is because
the analogue is able to bind the TCR and therefore competes with
(i) or (ii) for binding to the TCR.
[0045] T cells for use in the above binding experiments can be
isolated from patients with coeliac disease, for example with the
aid of the method of the invention. Other binding characteristics
of the analogue may also be the same as (i) or (ii), and thus
typically the analogue binds to the same MHC class II molecule to
which the peptide binds (HLA-DQ2). The analogue typically binds to
antibodies specific for (i) or (ii), and thus inhibits binding of
(i) or (ii) to such antibodies.
[0046] The analogue is typically a peptide. It may have homology
with (i) or (ii), typically at least 70% homology, preferably at
least 80, 90%, 95%, 97% or 99% homology with (i) or (ii), for
example over a region of at least 15 more (such as the entire
length of the analogue and/or (i) or (ii), or across the region
which contacts the TCR or binds the MHC molecule) contiguous amino
acids. Methods of measuring protein homology are well known in the
art and it will be understood by those of skill in the art that in
the present context, homology is calculated on the basis of amino
acid identity (sometimes referred to as "hard homology").
[0047] For example the UWGCG Package provides the BESTFIT program
which can be used to calculate homology (for example used on its
default settings) (Devereux et al (1984) Nucleic Acids Research 12,
p 387-395). The PILEUP and BLAST algorithms can be used to
calculate homology or line up sequences (typically on their default
settings), for example as described in Altschul S. F. (1993) J Mol
Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol
215:403-10.
[0048] Software for performing BLAST analyses is publicly available
through the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/). This algorithm involves first
identifying high scoring sequence pair HSPs) by identifying short
words of length W in the query sequence that either match or
satisfy some positive-valued threshold score T when aligned with a
word of the same length in a database sequence. T is referred to as
the neighbourhood word score threshold (Altschul et al, supra).
These initial neighbourhood word hits act as seeds for initiating
searches to find HSPs containing them. The word hits are extended
in both directions along each sequence for as far as the cumulative
alignment score can be increased. Extensions for the word hits in
each direction are halted when: the cumulative alignment score
falls off by the quantity X from its maximum achieved value; the
cumulative score goes to zero or below, due to the accumulation of
one or more negative-scoring residue alignments; or the end of
either sequence is reached. The BLAST algorithm parameters W, T and
X determine the sensitivity and speed of the alignment. The BLAST
program uses as defaults a word length (W) of 11, the BLOSUM62
scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad.
Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of
10, M=5, N=4, and a comparison of both strands.
[0049] The BLAST algorithm performs a statistical analysis of the
similarity between two sequences; see e.g., Karlin and Altschul
(1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of
similarity provided by the BLAST algorithm is the smallest sum
probability (P(N)), which provides an indication of the probability
by which a match between two nucleotide or amino acid sequences
would occur by chance. For example, a sequence is considered
similar to another sequence if the smallest sum probability in
comparison of the first sequence to the second sequence is less
than about 1, preferably less than about 0.1, more preferably less
than about 0.01, and most preferably less than about 0.001.
[0050] The homologous peptide analogues typically differ from (i)
or (ii) by 1, 2, 3, 4, 5, 6, 7, 8 or more mutations (which may be
substitutions, deletions or insertions). These mutation may be
measured across any of the regions mentioned above in relation to
calculating homology. The substitutions are preferably
`conservative`. These are defined according to the following Table.
Amino acids in the same block in the second column and preferably
in the same line in the third column may be substituted for each
other: TABLE-US-00001 ALIIPHATIC Non-polar GAP ILV Polar-uncharged
CSTM NQ Polar-charged DE KR AROMATIC HFWY
[0051] Typically the amino acids in the analogue at the equivalent
positions to amino acids in (i) or (ii) which contribute to binding
the MHC molecule or are responsible for the recognition by the TCR,
are the same or are conserved.
[0052] Typically the analogue peptide comprises one or more
modifications, which may be natural post-translation modifications
or artificial modifications. The modification may provide a
chemical moiety (typically by substitution of a hydrogen, e.g. of a
C--H bond), such as an amino, acetyl, hydroxy or halogen (e.g.
fluorine) group or carbohydrate group. Typically the modification
is present on the N or C terminus.
[0053] The analogue may comprise one or more non-natural amino
acids, for example amino acids with a side chain different from
natural amino acids. Generally, the non-natural amino acid will
have an N terminus and/or a C terminus. The non-natural amino acid
may be an L- or a D-amino acid.
[0054] The analogue typically has a shape, size, flexibility or
electronic configuration which is substantially similar to (i) or
(ii). It is typically a derivative of (i) or (ii). In one
embodiment the analogue is a fusion protein comprising the sequence
of SEQ ID NO:1 or 2, or any of the other peptides mentioned herein;
and non-gliadin sequence.
[0055] In one embodiment the analogue is or mimics (i) or (ii)
bound to a MHC class II molecule. 2, 3, 4 or more of such complexes
may be associated or bound to each other, for example using a
biotin/streptavidin based system, in which typically 2, 3 or 4
biotin labelled MHC molecules bind to a streptavidin moiety. This
analogue typically inhibits the binding of the (i) or (ii)/MHC
Class R complex to a TCR or antibody which is specific for the
complex.
[0056] The analogue is typically an antibody or a fragment of an
antibody, such as a Fab or (Fab).sub.2 fragment. The analogue may
be immobilised on a solid support, particularly an analogue which
mimics peptide bound to a MHC molecule.
[0057] The analogue is typically designed by computational means
and then synthesised using methods known in the art. Alternatively
the analogue can be selected from a library of compounds. The
library may be a combinatorial library or a display library, such
as a phage display library. The library of compounds may be
expressed in the display library in the form of being bound to a
MHC class II molecule, such as HLA-DQ2. Analogues are generally
selected from the library based on their ability to mimic the
binding characteristics (i) or (ii). Thus they may be selected
based on ability to bind a TCR or antibody which recognises (i) or
(ii).
[0058] Typically analogues will be recognised by T cells to at
least the same extent as any of the agents (i) or (ii), for example
at least to the same extent as the equivalent epitope and
preferably to the same extent as the peptide represented by SEQ ID
NO:2, is recognised in any of the assays described herein,
typically using T cells from coeliac disease patients. Analogues
may be recognised to these extents in vivo and thus may be able to
induce coeliac disease symptoms to at least the same extent as any
of the agents mentioned herein (e.g. in a human patient or animal
model).
[0059] Analogues may be identified in a method comprising
determining whether a candidate substance is recognised by a T cell
receptor that recognises an epitope of the invention, recognition
of the substance indicating that the substance is an analogue. Such
TCRs may be any of the TCRs mentioned herein, and may be present on
T cells. Any suitable assay mentioned herein can be used to
identify the analogue. In one embodiment this method is carried out
in vivo. As mentioned above preferred analogues are recognised to
at least the same extent as the peptide SEQ ID NO:2, and so the
method may be used to identify analogues which are recognised to
this extent.
[0060] In one embodiment the method comprises determining whether a
candidate substance is able to inhibit the recognition of an
epitope of the invention, inhibition of recognition indicating that
the substance is an analogue.
[0061] The agent may be a product comprising at least 2, 5, 10 or
20 agents as defined by (i), (ii) or (iii). Typically the
composition comprises epitopes of the invention (or equivalent
analogues) from different gliadins, such as any of the species or
variety of or types of gliadin mentioned herein. Preferred
compositions comprise at least one epitope of the invention, or
equivalent analogue, from all of the gliadins present in any of the
species or variety mentioned herein, or from 2, 3, 4 or more of the
species mentioned herein (such as from the panel of species
consisting of wheat, rye, barley, oats and triticale).
Diagnosis
[0062] As mentioned above the method of diagnosis of the invention
may be based on the detection of T cells which bind the agent or on
the detection of antibodies that recognise the agent.
[0063] The T cells which recognise the agent in the method (which
includes the use mentioned above) are generally T cells which have
been pre-sensitised in vivo to gliadin. As mentioned above such
antigen-experienced T cells have been found to be present in the
peripheral blood.
[0064] In the method the T cells can be contacted with the agent in
vitro or in vivo, and determining whether the T cells recognise the
agent can be performed in vitro or in vivo. Thus the invention
provides the agent for use in a method of diagnosis practiced on
the human body. Different agents are provided for simultaneous,
separate or sequential use in such a method.
[0065] The in vitro method is typically carried out in aqueous
solution into which the agent is added. The solution will also
comprise the T cells (and in certain embodiments the APCs discussed
below). The term `contacting` as used herein includes adding the
particular substance to the solution.
[0066] Determination of whether the T cells recognise the agent is
generally done by detecting a change in the state of the T cells in
the presence of the agent or determining whether the T cells bind
the agent. The change in state is generally caused by antigen
specific functional activity of the T cell after the TCR binds the
agent. The change of state may be measured inside (e.g. change in
intracellular expression of proteins) or outside (e.g. detection of
secreted substances) the T cells.
[0067] The change in state of the T cell may be the start of or
increase in secretion of a substance from the T cell, such as a
cytokine, especially IFN-.gamma., IL-2 or TNF-.alpha..
Determination of IFN-.gamma. secretion is particularly preferred.
The substance can typically be detected by allowing it to bind to a
specific binding agent and then measuring the presence of the
specific binding agent/substance complex. The specific binding
agent is typically an antibody, such as polyclonal or monoclonal
antibodies. Antibodies to cytokines are commercially available, or
can be made using standard techniques.
[0068] Typically the specific binding agent is immobilised on a
solid support. After the substance is allowed to bind the solid
support can optionally be washed to remove material which is not
specifically bound to the agent. The agent/substance complex may be
detected by using a second binding agent which will bind the
complex. Typically the second agent binds the substance at a site
which is different from the site which binds the first agent. The
second agent is preferably an antibody and is labelled directly or
indirectly by a detectable label.
[0069] Thus the second agent may be detected by a third agent which
is typically labelled directly or indirectly by a detectable label.
For example the second agent may comprise a biotin moiety, allowing
detection by a third agent which comprises a streptavidin moiety
and typically alkaline phosphatase as a detectable label.
[0070] In one embodiment the detection system which is used is the
ex-vivo ELISPOT assay described in WO 98/23960. In that assay
IFN-.gamma. secreted from the T cell is bound by a first
IFN-.gamma. specific antibody which is immobilised on a solid
support. The bound IFN-.gamma. is then detected using a second
IFN-.gamma. specific antibody which is labelled with a detectable
label. Such a labelled antibody can be obtained from MABTECH
(Stockholm, Sweden). Other detectable labels which can be used are
discussed below.
[0071] The change in state of the T cell which can be measured may
be the increase in the uptake of substances by the T cell, such as
the uptake of thymidine. The change in state may be an increase in
the size of the T cells, or proliferation of the T cells, or a
change in cell surface markers on the T cell.
[0072] In one embodiment the change of state is detected by
measuring the change in the intracellular expression of proteins,
for example the increase in intracellular expression of any of the
cytokines mentioned above. Such intracellular changes may be
detected by contacting the inside of the T cell with a moiety that
binds the expressed proteins in a specific manner and which allows
sorting of the T cells by flow cytometry.
[0073] In one embodiment when binding the TCR the agent is bound to
an MHC class II molecule (typically HLA-DQ2), which is typically
present on the surface of an antigen presenting cell (APC). However
as mentioned herein other agents can bind a TCR without the need to
also bind an MHC molecule.
[0074] Generally the T cells which are contacted in the method are
taken from the individual in a blood sample, although other types
of samples which contain T cells can be used. The sample may be
added directly to the assay or may be processed first. Typically
the processing may comprise diluting of the sample, for example
with water or buffer. Typically the sample is diluted from 1.5 to
100 fold, for example 2 to 50 or 5 to 10 fold.
[0075] The processing may comprise separation of components of the
sample. Typically mononuclear cells (MCs) are separated from the
samples. The MCs will comprise the T cells and APCs. Thus in the
method the APCs present in the separated MCs can present the
peptide to the T cells. In another embodiment only T cells, such as
only CD4 T cells, can be purified from the sample. PBMCs, MCs and T
cells can be separated from the sample using techniques known in
the art, such as those described in Lalvani et al (1997) J. Exp.
Med. 186, p 859-865.
[0076] In one embodiment the T cells used in the assay are in the
form of unprocessed or diluted samples, or are freshly isolated T
cells (such as in the form of freshly isolated MCs or PBMCs) which
are used directly ex vivo, i.e. they are not cultured before being
used in the method. Thus the T cells have not been restimulated in
an antigen specific manner in vitro. However the T cells can be
cultured before use, for example in the presence of one or more of
the agents, and generally also exogenous growth promoting
cytokines. During culturing the agent(s) are typically present on
the surface of APCs, such as the APC used in the method.
Pre-culturing of the T cells may lead to an increase in the
sensitivity of the method. Thus the T cells can be converted into
cell lines, such as short term cell lines (for example as described
in Ota et al (1990) Nature 346, p 183-187).
[0077] The APC which is typically present in the method may be from
the same individual as the T cell or from a different host. The APC
may be a naturally occurring APC or an artificial APC. The APC is a
cell which is capable of presenting the peptide to a T cell. It is
typically a B cell, dendritic cell or macrophage. It is typically
separated from the same sample as the T cell and is typically
co-purified with the T cell. Thus the APC may be present in MCs or
PBMCs. The APC is typically a freshly isolated ex vivo cell or a
cultured cell. It may be in the form of a cell line, such as a
short term or immortalised cell line. The APC may express empty MHC
class II molecules on its surface.
[0078] In the method one or more (different) agents may be used.
Typically the T cells derived from the sample can be placed into an
assay with all the agents which it is intended to test or the T
cells can be divided and placed into separate assays each of which
contain one or more of the agents.
[0079] The invention also provides the agents such as two or more
of any of the agents mentioned herein (e.g. the combinations of
agents which are present in the composition agent discussed above)
for simultaneous separate or sequential use (eg. for in vivo
use).
[0080] In one embodiment agent per se is added directly to an assay
comprising T cells and APCs. As discussed above the T cells and
APCs in such an assay could be in the form of MCs. When agents
which can be recognised by the T cell without the need for
presentation by APCs are used then APCs are not required. Analogues
which mimic the original (i) or (ii) bound to a MHC molecule are an
example of such an agent.
[0081] In one embodiment the agent is provided to the APC in the
absence of the T cell. The APC is then provided to the T cell,
typically after being allowed to present the agent on its surface.
The peptide may have been taken up inside the APC and presented, or
simply be taken up onto the surface without entering inside the
APC.
[0082] The duration for which the agent is contacted with the T
cells will vary depending on the method used for determining
recognition of the peptide. Typically 10.sup.5 to 10.sup.7,
preferably 5.times.10.sup.5 to 10.sup.6 PBMCs are added to each
assay. In the case where agent is added directly to the assay its
concentration is from 10.sup.-1 to 10.sup.3 .mu.g/ml, preferably
0.5 to 50 .mu.g/ml or 1 to 10 .mu.g/ml.
[0083] Typically the length of time for which the T cells are
incubated with the agent is from 4 to 24 hours, preferably 6 to 16
hours. When using ex vivo PBMCs it has been found that
0.3.times.10.sup.6 PBMCs can be incubated in 10 .mu.g/ml of peptide
for 12 hours at 37.degree. C.
[0084] The determination of the recognition of the agent by the T
cells may be done by measuring the binding of the agent to the T
cells (this can be carried out using any suitable binding assay
format discussed herein). Typically T cells which bind the agent
can be sorted based on this binding, for example using a FACS
machine. The presence of T cells which recognise the agent will be
deemed to occur if the frequency of cells sorted using the agent is
above a `control` value. The frequency of antigen-experienced T
cells is generally 1 in 10.sup.6 to 1 in 10.sup.3, and therefore
whether or not the sorted cells are antigen-experienced T cells can
be determined.
[0085] The determination of the recognition of the agent by the T
cells may be measured in vivo. Typically the agent is administered
to the host and then a response which indicates recognition of the
agent may be measured. The agent is typically administered
intradermally or epidermally. The agent is typically administered
by contacting with the outside of the skin, and may be retained at
the site with the aid of a plaster or dressing. Alternatively the
agent may be administered by needle, such as by injection, but can
also be administered by other methods such as ballistics (e.g. the
ballistics techniques which have been used to deliver nucleic
acids). EP-A-0693119 describes techniques which can typically be
used to administer the agent. Typically from 0.001 to 1000 .mu.g,
for example from 0.01 to 100 .mu.g or 0.1 to 10 .mu.g of agent is
administered.
[0086] In one embodiment a product can be administered which is
capable of providing the agent in vivo. Thus a polynucleotide
capable of expressing the agent can be administered, typically in
any of the ways described above for the administration of the
agent. The polynucleotide typically has any of the characteristics
of the polynucleotide provided by the invention which is discussed
below. The agent is expressed from the polynucleotide in vivo.
Typically from 0.001 to 1000 .mu.g, for example from 0.01 to 100
.mu.g or 0.1 to 10 .mu.g of polynucleotide is administered.
[0087] Recognition of the agent administered to the skin is
typically indicated by the occurrence of inflammation (e.g.
induration, erythema or oedema) at the site of administration. This
is generally measured by visual examination of the site.
[0088] The method of diagnosis based on the detection of an
antibody that binds the agent is typically carried out by
contacting a sample from the individual (such as any of the samples
mentioned here, optionally processed in any manner mentioned
herein) with the agent and determining whether an antibody in the
sample binds the agent, such a binding indicating that the
individual has, or is susceptible to coeliac disease. Any suitable
format of binding assay may be used, such as any such format
mentioned herein.
Therapy
[0089] The identification of the immunodominant epitope allows the
therapeutic products to be made which target the T cells which
recognise this epitope (such T cells being ones which participate
in the immune response against gliadin). This finding also allows
the prevention or treatment of coeliac disease by suppressing (by
tolerisation) an antibody or T cell response to the epitope.
[0090] Certain agents of the invention bind the TCR which
recognises the epitope of the invention (as measured using any of
the binding assays discussed above) and cause tolerisation of the T
cell that carries the TCR. Such agents, optionally in association
with a carrier, can therefore be used to prevent or treat coeliac
disease.
[0091] Generally tolerisation can be caused by the same peptides
which can (after being recognised by the TCR) cause antigen
specific functional activity of the T cell (such as any such
activity mentioned herein, e.g. secretion of cytokines). Such
agents cause tolerisation when they are presented to the immune
system in a `tolerising` context.
[0092] Tolerisation leads to a decrease in the recognition of a T
cell or antibody epitope by the immune system. In the case of a T
cell epitope this can be caused by the deletion or anergising of T
cells which recognise the epitope. Thus T cell activity (for
example as measured in suitable assays mentioned herein) in
response to the epitope is decreased. Tolerisation of an antibody
response means that a decreased amount of specific antibody to the
epitope is produced when the epitope is administered.
[0093] Methods of presenting antigens to the immune system in such
a context are known and are described for example in Yoshida et al.
Clin. Immunol. Immunopathol. 82, 207-215 (1997), Thurau et al.
Clin. Exp. Immunol. 109, 370-6 (1997), and Weiner et al. Res.
Immunol. 148, 528-33 (1997). In particular certain routes of
administration can cause tolerisation, such as oral, nasal or
intraperitoneal. Particular products which cause tolerisation may
be administered (e.g. in a composition which also comprises the
agent) to the individual. Such products include cytokines, such as
cytokines which favour a Th2 response (e.g. IL-4, TGF-.beta. or
IL-10). Products or agent may be administered at a dose which
causes tolerisation.
[0094] The invention provides a protein which comprises a sequence
able to act as an antagonist of the T cell (which T cell recognises
the agent). Such proteins and such antagonists can also be used to
prevent or treat coeliac disease. The antagonist will cause a
decrease in the T cell response. In one embodiment the antagonist
binds the TCR of the T cell (generally in the form of a complex
with HLA-DQ2) but instead of causing normal functional activation
causing an abnormal signal to be passed through the TCR
intracellular signalling cascade which causes the T cell to have
decreased function activity (e.g. in response to recognition of an
epitope, typically as measured by any suitable assay mentioned
herein).
[0095] In one embodiment the antagonist competes with epitope to
bind a component of MHC processing and presentation pathway, such
as an MHC molecule (typically HLA-DQ2). Thus the antagonist may
bind HLA-DQ2 (and thus be a peptide presented by this MHC
molecule), such as peptide TP (Table 10) or a homologue
thereof.
[0096] Methods of causing antagonism are known in the art. In one
embodiment the antagonist is a homologue of the epitopes mentioned
above and may have any of the sequence, binding or other properties
of the agent (particularly analogues). The antagonists typically
differ from any of the above epitopes (which are capable of causing
a normal antigen specific function in the T cell) by 1, 2, 3, 4 or
more mutations (each of which may be a substitution, insertion or
deletion). Such antagonists are termed "altered peptide ligands" or
"APL" in the art. The mutations are typically at the amino acid
positions which contact the TCR.
[0097] The antagonist may differ from the epitope by a substitution
within the sequence which is equivalent to the sequence represented
by amino acids 65 to 67 of A-gliadin (such antagonists are shown in
Table 9). Thus preferably the antagonist has a substitution at the
equivalent of position 64, 65 or 67. Preferably the substitution is
64W, 67W, 67M or 65T.
[0098] Since the T cell immune response to the epitope of the
invention in an individual is polyclonal more than one antagonist
may need to be administered to cause antagonism of T cells of the
response which have different TCRs. Therefore the antagonists may
be administered in a composition which comprises at least 2, 4, 6
or more different antagonists, which each antagonise different T
cells.
[0099] The invention also provides a method of identifying an
antagonist of a T cell (which recognises the agent) comprising
contacting a candidate substance with the T cell and detecting
whether the substance causes a decrease in the ability of the T
cell to undergo an antigen specific response (e.g. using any
suitable assay mentioned herein), the detecting of any such
decrease in said ability indicating that the substance is an
antagonist.
[0100] In one embodiment the antagonists (including combinations of
antagonists to a particular epitope) or tolerising (T cell and
antibody tolerising) agents are present in a composition comprising
at least 2, 4, 6 or more antagonists or agents which antagonise or
tolerise to different epitopes of the invention, for example to the
combinations of epitopes discussed above in relation to the agents
which are a product comprising more than one substance.
Testing Whether a Composition is Capable of Causing Coeliac
Disease
[0101] As mentioned above the invention provides a method of
determining whether a composition is capable of causing coeliac
disease comprising detecting the presence of a protein sequence
which is capable of being modified by a transglutaminase to as
sequence comprising the agent or epitope of the invention (such
transglutaminase activity may be a human intestinal
transglutaminase activity). Typically this is performed by using a
binding assay in which a moiety which binds to the sequence in a
specific manner is contacted with the composition and the formation
of sequence/moiety complex is detected and used to ascertain the
presence of the agent. Such a moiety may be any suitable substance
(or type of substance) mentioned herein, and is typically a
specific antibody. Any suitable format of binding assay can be used
(such as those mentioned herein).
[0102] In one embodiment the composition is contacted with at least
2, 5, 10 or more antibodies which are specific for epitopes of the
invention from different gliadins, for example a panel of
antibodies capable of recognising the combinations of epitopes
discussed above in relation to agents of the invention which are a
product comprising more than one substance.
[0103] The composition typically comprises material from a plant
that expresses a gliadin which is capable of causing coeliac
disease (for example any of the gliadins or plants mentioned
herein). Such material may be a plant part, such as a harvested
product (e.g. seed). The material may be processed products of the
plant material (e.g. any such product mentioned herein), such as a
flour or food that comprises the gliadin. The processing of food
material and testing in suitable binding assays is routine, for
example as mentioned in Kricka L J, J. Biolumin. Chemilumin. 13,
189-93 (1998).
Binding Assays
[0104] The determination of binding between any two substances
mentioned herein may be done by measuring a characteristic of
either or both substances that changes upon binding, such as a
spectroscopic change.
[0105] The binding assay format may be a `band shift` system. This
involves determining whether the presence of one substance (such as
a candidate substance) advances or retards the progress of the
other substance during gel electrophoresis.
[0106] The format may be a competitive binding method which
determines whether the one substance is able to inhibit the binding
of the other substance to an agent which is known to bind the other
substance, such as a specific antibody.
Mutant Gliadin Proteins
[0107] The invention provides a gliadin protein in which an epitope
sequence of the invention, or sequence which can be modified by a
transglutaminase to provide such a sequence has been mutated so
that it no longer causes, or is recognised by, a T cell response
that recognises the epitope. In this context the term recognition
refers to the TCR binding the epitope in such a way that normal
(not antagonistic) antigen-specific functional activity of the T
cell occurs.
[0108] Methods of identifying equivalent epitopes in other gliadins
are discussed above. The wild type of the mutated gliadin is one
which causes coeliac disease. Such a gliadin will have homology
with SEQ ID NO:3, for example to the degree mentioned above (in
relation to the analogue) across all of SEQ ID NO:3 or across 15,
30, 60, 100 or 200 contiguous amino acids of SEQ ID NO:3.
[0109] The mutated gliadin will not cause coeliac disease or will
cause decreased symptoms of coeliac disease. Typically the mutation
decreases the ability of the epitope to induce a T cell response.
The mutated epitope may have a decreased binding to HLA-DQ2, a
decreased ability to be presented by an APC or a decreased ability
to bind to or to be recognised (i.e. cause antigen-specific
functional activity) by T cells that recognise the agent. The
mutated gliadin or epitope will therefore show no or reduced
recognition in any of the assays mentioned herein in relation to
the diagnostic aspects of the invention.
[0110] The mutation may be one or more deletions, additions or
substitutions of length 1 to 3, 4 to 6, 6 to 10, 11 to 15 or more
in the epitope, for example across the sequence SEQ ID NO:2 or its
equivalent. Preferably the mutant gliadin has at least one mutation
in the sequence SEQ ID NO:1. A preferred mutation is at position 65
in A-gliadin (or in an equivalent position in other gliadins).
Typically the naturally occurring glutamine at this position is
substituted to any of the amino acids shown in Table 3, preferably
to histidine, tyrosine, tryptophan, lysine, proline, or
arginine.
[0111] The invention thus also provides use of a mutation (such any
of the mutations in any of the sequences discussed herein) in an
epitope of a gliadin protein, which epitope is an epitope of the
invention, to decrease the ability of the gliadin protein to cause
coeliac disease.
[0112] In one embodiment the mutated sequence is able to act as an
antagonist. Thus the invention provides a protein that comprises a
sequence which is able to bind to a T cell receptor, which T cell
receptor recognises an agent of the invention, and which sequence
is able to cause antagonism of a T cell that carries such a T cell
receptor.
[0113] The invention also provides proteins which are fragments of
the above mutant gliadin proteins, which are at least 15 amino
acids long (e.g. at least 30, 60, 100, 150, 200, or 250 amino acids
long) and which comprise the mutations discussed above which
decrease the ability of the gliadin to be recognised. Any of the
mutant proteins (including fragments) mentioned herein may also be
present in the form of fusion proteins, for example with other
gliadins or with non-gliadin proteins.
[0114] The equivalent wild type protein to the mutated gliadin
protein is typically from a graminaceous monocotyledon, such as a
plant of genus Triticum, e.g. wheat, rye, barley, oats or
triticale. The protein is typically an .alpha., .alpha..beta.,
.beta., .gamma. or .omega. gliadin. The gliadin may be an
A-gliadin.
Kits
[0115] The invention also provides a kit for carrying out the
method comprising one or more agents and optionally a means to
detect the recognition of the agent by the T cell. Typically the
different agents are provided for simultaneous, separate or
sequential use. Typically the means to detect recognition allows or
aids detection based on the techniques discussed above.
[0116] Thus the means may allow detection of a substance secreted
by the T cells after recognition. The kit may thus additionally
include a specific binding moiety for the substance, such as an
antibody. The moiety is typically specific for IFN-.gamma.. The
moiety is typically immobilised on a solid support. This means that
after binding the moiety the substance will remain in the vicinity
of the T cell which secreted it. Thus `spots` of substance/moiety
complex are formed on the support, each spot representing a T cell
which is secreting the substance. Quantifying the spots, and
typically comparing against a control, allows determination of
recognition of the agent.
[0117] The kit may also comprise a means to detect the
substance/moiety complex. A detectable change may occur in the
moiety itself after binding the substance, such as a colour change.
Alternatively a second moiety directly or indirectly labelled for
detection may be allowed to bind the substance/moiety complex to
allow the determination of the spots. As discussed above the second
moiety may be specific for the substance, but binds a different
site on the substance than the first moiety.
[0118] The immobilised support may be a plate with wells, such as a
microtitre plate. Each assay can therefore be carried out in a
separate well in the plate.
[0119] The kit may additionally comprise medium for the T cells,
detection moieties or washing buffers to be used in the detection
steps. The kit may additionally comprise reagents suitable for the
separation from the sample, such as the separation of PBMCs or T
cells from the sample. The kit may be designed to allow detection
of the T cells directly in the sample without requiring any
separation of the components of the sample.
[0120] The kit may comprise an instrument which allows
administration of the agent, such as intradermal or epidermal
administration. Typically such an instrument comprises plaster,
dressing or one or more needles. The instrument may allow ballistic
delivery of the agent. The agent in the kit may be in the form of a
pharmaceutical composition.
[0121] The kit may also comprise controls, such as positive or
negative controls. The positive control may allow the detection
system to be tested. Thus the positive control typically mimics
recognition of the agent in any of the above methods. Typically in
the kits designed to determine recognition in vitro the positive
control is a cytokine. In the kit designed to detect in vivo
recognition of the agent the positive control may be antigen to
which most individuals should response.
[0122] The kit may also comprise a means to take a sample
containing T cells from the host, such as a blood sample. The kit
may comprise a means to separate mononuclear cells or T cells from
a sample from the host.
Polynucleotides, Cells, Transgenic Mammals and Antibodies
[0123] The invention also provides a polynucleotide which is
capable of expression to provide the agent or mutant gliadin
proteins. Typically the polynucleotide is DNA or RNA, and is single
or double stranded. The polynucleotide will preferably comprise at
least 50 bases or base pairs, for example 50 to 100, 100 to 500,
500 to 1000 or 1000 to 2000 or more bases or base pairs. The
polynucleotide therefore comprises sequence which encodes the
sequence of SEQ ID NO: 1 or 2 or any of the agents mentioned
herein. To the 5' and 3' of this coding sequence the polynucleotide
of the invention has sequence or codons which are different from
the sequence or codons 5' and 3' to these sequences in the
corresponding gliadin gene.
[0124] 5' and/or 3' to the sequence encoding the peptide the
polynucleotide has coding or non-coding sequence. Sequence 5'
and/or 3' to the coding sequence may comprise sequences which aid
expression, such as transcription and/or translation, of the
sequence encoding the agent. The polynucleotide may be capable of
expressing the agent prokaryotic or eukaryotic cell. In one
embodiment the polynucleotide is capable of expressing the agent in
a mammalian cell, such as a human, primate or rodent (e.g. mouse or
rat) cell.
[0125] A polynucleotide of the invention may hybridise selectively
to a polynucleotide that encodes SEQ ID NO:3 at a level
significantly above background. Selective hybridisation is
typically achieved using conditions of medium to high stringency
(for example 0.03M sodium chloride and 0.03M sodium citrate at from
about 50.degree. C. to about 60.degree. C.). However, such
hybridisation may be carried out under any suitable conditions
known in the art (see Sambrook et al (1989), Molecular Cloning: A
Laboratory Manual). For example, if high stringency is required,
suitable conditions include 0.2.times.SSC at 60.degree. C. If lower
stringency is required, suitable conditions include 2.times.SSC at
60.degree. C.
[0126] Agents or proteins of the invention may be encoded by the
polynucleotides described herein.
[0127] The polynucleotide may form or be incorporated into a
replicable vector. Such a vector is able to replicate in a suitable
cell. The vector may be an expression vector. In such a vector the
polynucleotide of the invention is operably linked to a control
sequence which is capable of providing for the expression of the
polynucleotide. The vector may contain a selectable marker, such as
the ampicillin resistance gene.
[0128] The polynucleotide or vector may be present in a cell. Such
a cell may have been transformed by the polynucleotide or vector.
The cell may express the agent. The cell will be chosen to be
compatible with the said vector and may for example be a
prokaryotic (bacterial), yeast, insect or mammalian cell. The
polynucleotide or vector may be introduced into host cells using
conventional techniques including calcium phosphate precipitation,
DEAE-dextran transfection, or electroporation.
[0129] The invention provides processes for the production of the
proteins of the invention by recombinant means. This may comprise
(a) cultivating a transformed cell as defined above under
conditions that allow the expression of the protein; and preferably
(b) recovering the expressed polypeptide. Optionally, the
polypeptide may be isolated and/or purified, by techniques known in
the art.
[0130] The invention also provides TCRs which recognise (or bind)
the agent, or fragments thereof which are capable of such
recognition (or binding). These can be present in the any form
mentioned herein (e.g. purity) discussed herein in relation to the
protein of the invention. The invention also provides T cells which
express such TCRs which can be present in any form (e.g. purity)
discussed herein for the cells of the invention.
[0131] The invention also provides monoclonal or polyclonal
antibodies which specifically recognise the agents (such as any of
the epitopes of the invention) and which recognise the mutant
gliadin proteins (and typically which do not recognise the
equivalent wild-type gliadins) of the invention, and methods of
making such antibodies. Antibodies of the invention bind
specifically to these substances of the invention.
[0132] For the purposes of this invention, the term "antibody"
includes antibody fragments such as Fv, F(ab) and F(ab).sub.2
fragments, as well as single-chain antibodies.
[0133] A method for producing a polyclonal antibody comprises
immunising a suitable host animal, for example an experimental
animal, with the immunogen and isolating immunoglobulins from the
serum. The animal may therefore be inoculated with the immunogen,
blood subsequently removed from the animal and the IgG fraction
purified. A method for producing a monoclonal antibody comprises
immortalising cells which produce the desired antibody. Hybridoma
cells may be produced by fusing spleen cells from an inoculated
experimental animal with tumour cells (Kohler and Milstein (1975)
Nature 256, 495-497).
[0134] An immortalized cell producing the desired antibody may be
selected by a conventional procedure. The hybridomas may be grown
in culture or injected intraperitoneally for formation of ascites
fluid or into the blood stream of an allogenic host or
immunocompromised host. Human antibody may be prepared by in vitro
immunisation of human lymphocytes, followed by transformation of
the lymphocytes with Epstein-Barr virus.
[0135] For the production of both monoclonal and polyclonal
antibodies, the experimental animal is suitably a goat, rabbit, rat
or mouse. If desired, the immunogen may be administered as a
conjugate in which the immunogen is coupled, for example via a side
chain of one of the amino acid residues, to a suitable carrier. The
carrier molecule is typically a physiologically acceptable carrier.
The antibody obtained may be isolated and, if desired,
purified.
[0136] The polynucleotide, agent, protein or antibody of the
invention, may carry a detectable label. Detectable labels which
allow detection of the secreted substance by visual inspection,
optionally with the aid of an optical magnifying means, are
preferred. Such a system is typically based on an enzyme label
which causes colour change in a substrate, for example alkaline
phosphatase causing a colour change in a substrate. Such substrates
are commercially available, e.g. from BioRad. Other suitable labels
include other enzymes such as peroxidase, or protein labels, such
as biotin; or radioisotopes, such as .sup.32P or .sup.35S. The
above labels may be detected using known techniques.
[0137] Polynucleotides, agents, proteins, antibodies or cells of
the invention may be in substantially purified form. They may be in
substantially isolated form, in which case they will generally
comprise at least 80% e.g. at least 90, 95, 97 or 99% of the
polynucleotide, peptide, antibody, cells or dry mass in the
preparation. The polynucleotide, agent, protein or antibody is
typically substantially free of other cellular components. The
polynucleotide, agent, protein or antibody may be used in such a
substantially isolated, purified or free form in the method or be
present in such forms in the kit.
[0138] The invention also provides a transgenic mammal which
expresses a TCR of the invention. This may be any of the mammals
discussed herein (e.g. in relation to the production of the
antibody). Preferably the mammal has, or is susceptible, to coeliac
disease. The mammal may also express HLA-DQ2 and/or may be given a
diet comprising a gliadin which cause coeliac disease (e.g. any of
the gliadin proteins mentioned herein). Thus the mammal may act as
an animal model for coeliac disease.
[0139] The invention also provides a method of identifying a
product which is therapeutic for coeliac disease comprising
administering a candidate substance to a mammal of the invention
which has, or which is susceptible to, coeliac disease and
determining whether substance prevents or treats coeliac disease in
the mammal, the prevention or treatment of coeliac disease
indicating that the substance is a therapeutic product. Such a
product may be used to treat or prevent coeliac disease.
[0140] The invention provides therapeutic (including prophylactic)
agents or diagnostic substances (the agents, proteins and
polynucleotides of the invention). These substances are formulated
for clinical administration by mixing them with a pharmaceutically
acceptable carrier or diluent. For example they can be formulated
for topical, parenteral, intravenous, intramuscular, subcutaneous,
intraocular, intradermal, epidermal or transdermal administration.
The substances may be mixed with any vehicle which is
pharmaceutically acceptable and appropriate for the desired route
of administration. The pharmaceutically carrier or diluent for
injection may be, for example, a sterile or isotonic solution such
as Water for Injection or physiological saline, or a carrier
particle for ballistic delivery.
[0141] The dose of the substances may be adjusted according to
various parameters, especially according to the agent used; the
age, weight and condition of the patient to be treated; the mode of
administration used; the severity of the condition to be treated;
and the required clinical regimen. As a guide, the amount of
substance administered by injection is suitably from 0.01 mg/kg to
30 mg/kg, preferably from 0.1 mg/kg to 10 mg/kg.
[0142] The routes of administration and dosages described are
intended only as a guide since a skilled practitioner will be able
to determine readily the optimum route of administration and dosage
for any particular patient and condition.
[0143] The substances of the invention may thus be used in a method
of treatment of the human or animal body, or in a diagnostic method
practised on the human body. In particular they may be used in a
method of treating or preventing coeliac disease. The invention
also provide the agents for use in a method of manufacture of a
medicament for treating or preventing coeliac disease. Thus the
invention provides a method of preventing or treating coeliac
disease comprising administering to a human in need thereof a
substance of the invention (typically a non-toxic effective amount
thereof).
[0144] The agent of the invention can be made using standard
synthetic chemistry techniques, such as by use of an automated
synthesizer. The agent may be made from a longer polypeptide e.g. a
fusion protein, which polypeptide typically comprises the sequence
of the peptide. The peptide may be derived from the polypeptide by
for example hydrolysing the polypeptide, such as using a protease;
or by physically breaking the polypeptide. The polynucleotide of
the invention can be made using standard techniques, such as by
using a synthesiser.
Plant Cells and Plants that Express Mutant Gliadin Proteins or
Express Proteins Comprising Sequences which can Act as
Antagonists
[0145] The cell of the invention may be a plant cell, such as a
cell of a graminaceous monocotyledonous species. The species may be
one whose wild-type form expresses gliadins, such as any of the
gliadin proteins mentioned herein (including gliadins with any
degree of homology to SEQ ID NO:3 mentioned herein). Such a gliadin
may cause coeliac disease in humans. The cell may be of wheat,
maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane.
Typically the cell is of the Triticum genus, such as aestivum,
spelta, polonicum or monococcum.
[0146] The plant cell of the invention is typically one which does
not express a wild-type gliadin (such as any of the gliadins
mentioned herein which may cause coeliac disease), or one which
does not express a gliadin comprising a sequence that can be
recognised by a T cell that recognises the agent. Thus if the
wild-type plant cell did express such a gliadin then it may be
engineered to prevent or reduce the expression of such a gliadin or
to change the amino acid sequence of the gliadin so that it no
longer causes coeliac disease (typically by no longer expressing
the epitope of the invention).
[0147] This can be done for example by introducing mutations into
1, 2, 3 or more or all of such gliadin genes in the cell, for
example into coding or non-coding (e.g. promoter regions). Such
mutations can be any of the type or length of mutations discussed
herein (e.g in relation to homologous proteins). The mutations can
be introduced in a directed manner (e.g using site directed
mutagenesis or homologous recombination techniques) or in a random
manner (e.g. using a mutagen, and then typically selecting for
mutagenised cells which no longer express the gliadin (or a gliadin
sequence which causes coeliac disease)).
[0148] In the case of plants or plant cells that express a protein
that comprises a sequence able to act as an antagonist such a plant
or plant cell may express a wild-type gliadin protein (e.g. one
which causes coeliac disease). Preferably though the presence of
the antagonist sequence will cause reduced coeliac disease symptoms
(such as no symptoms) in an individual who ingests a food
comprising protein from the plant or plant cell.
[0149] The polynucleotide which is present in (or which was
transformed into) the plant cell will generally comprise promoter
capable of expressing the mutant gliadin protein the plant cell.
Depending on the pattern of expression desired, the promoter may be
constitutive, tissue- or stage-specific; and/or inducible. For
example, strong constitutive expression in plants can be obtained
with the CAMV 35S, Rubisco ssu, or histone promoters. Also,
tissue-specific or stage-specific promoters may be used to target
expression of protein of the invention to particular tissues in a
transgenic plant or to particular stages in its development. Thus,
for example seed-specific, root-specific, leaf-specific,
flower-specific etc promoters may be used. Seed-specific promoters
include those described by Dalta et al (Biotechnology Ann. Rev.
(1997), 3, pp. 269-296). Particular examples of seed-specific
promoters are napin promoters (EP-A-0 255, 378), phaseolin
promoters, glutenine promoters, helianthenine promoters
(WO92/17580), albumin promoters (WO98/45460), oleosin promoters
(WO98/45461) and ATS1 and ATS3 promoters PCT/US98/06798).
[0150] The cell may be in any form. For example, it may be an
isolated cell, e.g. a protoplast, or it may be part of a plant
tissue, e.g. a callus, or a tissue excised from a plant, or it may
be part of a whole plant. The cell may be of any type (e.g of any
type of plant part). For example, an undifferentiated cell, such as
a callus cell; or a differentiated cell, such as a cell of a type
found in embryos, pollen, roots, shoots or leaves. Plant parts
include roots; shoots; leaves; and parts involved in reproduction,
such as pollen, ova, stamens, anthers, petals, sepals and other
flower parts.
[0151] The invention provides a method of obtaining a transgenic
plant cell comprising transforming a plant cell with a
polynucleotide or vector of the invention to give a transgenic
plant cell. Any suitable transformation method may be used (in the
case of wheat the techniques disclosed in Vasil V et al,
Biotechnology 10, 667-674 (1992) may be used). Preferred
transformation techniques include electroporation of plant
protoplasts and particle bombardment. Transformation may thus give
rise to a chimeric tissue or plant in which some cells are
transgenic and some are not.
[0152] The cell of the invention or thus obtained cell may be
regenerated into a transgenic plant by techniques known in the art.
These may involve the use of plant growth substances such as
auxins, giberellins and/or cytokinins to stimulate the growth
and/or division of the transgenic cell. Similarly, techniques such
as somatic embryogenesis and meristem culture may be used.
Regeneration techniques are well known in the art and examples can
be found in, e.g. U.S. Pat. No. 4,459,355, U.S. Pat. No. 4,536,475,
U.S. Pat. No. 5,464,763, U.S. Pat. No. 5,177,010, U.S. Pat. No.
5,187,073, EP 267,159, EP 604,662, EP 672,752, U.S. Pat. No.
4,945,050, U.S. Pat. No. 5,036,006, U.S. Pat. No. 5,100,792, U.S.
Pat. No. 5,371,014, U.S. Pat. No. 5,478,744, U.S. Pat. No.
5,179,022, U.S. Pat. No. 5,565,346, U.S. Pat. No. 5,484,956, U.S.
Pat. No. 5,508,468, U.S. Pat. No. 5,538,877, U.S. Pat. No.
5,554,798, U.S. Pat. No. 5,489,520, U.S. Pat. No. 5,510,318, U.S.
Pat. No. 5,204,253, U.S. Pat. No. 5,405,765, EP 442,174, EP
486,233, EP 486,234, EP 539,563, EP 674,725, WO91/02071 and WO
95/06128.
[0153] In many such techniques, one step is the formation of a
callus, i.e. a plant tissue comprising expanding and/or dividing
cells. Such calli are a further aspect of the invention as are
other types of plant cell cultures and plant parts. Thus, for
example, the invention provides transgenic plant tissues and parts,
including embryos, meristems, seeds, shoots, roots, stems, leaves
and flower parts. These may be chimeric in the sense that some of
their cells are cells of the invention and some are not. Transgenic
plant parts and tissues, plants and seeds of the invention may be
of any of the plant species mentioned herein.
[0154] Regeneration procedures will typically involve the selection
of transformed cells by means of marker genes.
[0155] The regeneration step gives rise to a first generation
transgenic plant. The invention also provides methods of obtaining
transgenic plants of further generations from this first generation
plant. These are known as progeny transgenic plants. Progeny plants
of second, third, fourth, fifth, sixth and further generations may
be obtained from the first generation transgenic plant by any means
known in the art.
[0156] Thus, the invention provides a method of obtaining a
transgenic progeny plant comprising obtaining a second-generation
transgenic progeny plant from a first-generation transgenic plant
of the invention, and optionally obtaining transgenic plants of one
or more further generations from the second-generation progeny
plant thus obtained.
[0157] Progeny plants may be produced from their predecessors of
earlier generations by any known technique. In particular, progeny
plants may be produced by:
obtaining a transgenic seed from a transgenic plant of the
invention belonging to a previous generation, then obtaining a
transgenic progeny plant of the invention belonging to a new
generation by growing up the transgenic seed; and/or
propagating clonally a transgenic plant of the invention belonging
to a previous generation to give a transgenic progeny plant of the
invention belonging to a new generation; and/or
crossing a first-generation transgenic plant of the invention
belonging to a previous generation with another compatible plant to
give a transgenic progeny plant of the invention belonging to a new
generation; and optionally
obtaining transgenic progeny plants of one or more further
generations from the progeny plant thus obtained.
[0158] These techniques may be used in any combination. For
example, clonal propagation and sexual propagation may be used at
different points in a process that gives rise to a transgenic plant
suitable for cultivation. In particular, repetitive back-crossing
with a plant taxon with agronomically desirable characteristics may
be undertaken. Further steps of removing cells from a plant and
regenerating new plants therefrom may also be carried out.
[0159] Also, further desirable characteristics may be introduced by
transforming the cells, plant tissues, plants or seeds, at any
suitable stage in the above process, to introduce desirable coding
sequences other than the polynucleotides of the invention. This may
be carried out by the techniques described herein for the
introduction of polynucleotides of the invention.
[0160] For example, further transgenes may be selected from those
coding for other herbicide resistance traits, e.g. tolerance to:
Glyphosate (e.g. using an EPSP synthase gene (e.g. EP-A-0 293,358)
or a glyphosate oxidoreductase (WO 92/000377) gene); or tolerance
to fosametin; a dihalobenzonitrile; glufosinate, e.g. using a
phosphinothricin acetyl transferase (PAT) or glutamine synthase
gene (cf. EP-A-0 242,236); asulam; e.g. using a dihydropteroate
synthase gene (EP-A-0 369,367); or a sulphonylurea, e.g. using an
ALS gene); diphenyl ethers such as acifluorfen or oxyfluorfen, e.g.
using a protoporphyrogen oxidase gene); an oxadiazole such as
oxadiazon; a cyclic imide such as chlorophthalim; a phenyl pyrazole
such as TNP, or a phenopylate or carbamate analogue thereof.
[0161] Similarly, genes for beneficial properties other than
herbicide tolerance may be introduced. For example, genes for
insect resistance may be introduced, notably genes encoding
Bacillus thuringiensis (Bt) toxins. Likewise, genes for disease
resistance may be introduced, e.g. as in WO91/02701 or
WO95/06128.
[0162] Typically, a protein of the invention is expressed in a
plant of the invention. Depending on the promoter used, this
expression may be constitutive or inducible. Similarly, it may be
tissue- or stage-specific, i.e. directed towards a particular plant
tissue (such as any of the tissues mentioned herein) or stage in
plant development.
[0163] The invention also provides methods of obtaining crop
products by harvesting, and optionally processing further,
transgenic plants of the invention. By crop product is meant any
useful product obtainable from a crop plant.
Products that Contain Mutant Gliadin Proteins or Proteins that
Comprise Sequence Capable of Acting as an Antagonist
[0164] The invention provides a product that comprises the mutant
gliadin proteins or protein that comprises sequence capable of
acting as an antagonist. This is typically derived from or comprise
plant parts from plants mentioned herein which express such
proteins. Such a product may be obtainable directly by harvesting
or indirectly, by harvesting and further processing the plant of
the invention. Directly obtainable products include grains.
Alternatively, such a product may be obtainable indirectly, by
harvesting and further processing. Examples of products obtainable
by further processing are flour or distilled alcoholic beverages;
food products made from directly obtained or further processed
material, e.g. baked products (e.g. bread) made from flour.
Typically such food products, which are ingestible and digestible
(i.e. non-toxic and of nutrient value) by human individuals.
[0165] In the case of food products that comprise the protein which
comprises an antagonist sequence the food product may also comprise
wild-type gliadin, but preferably the antagonist is able to cause a
reduction (e.g. completely) in the coeliac disease symptoms after
such food is ingested.
[0166] The invention is illustrated by the following Examples:
Example 1
[0167] We carried out epitope mapping in Coeliac disease by using a
set of 51 synthetic 15-mer peptides that span the complete sequence
of a fully characterized a-gliadin, "A-gliadin" (see Table 1).
A-Gliadin peptides were also individually treated with tTG to
generate products that might mimic those produced in vivo.sup.3. We
also sought to study Coeliac disease patients at the point of
initiation of disease relapse to avoid the possibility that epitope
"spreading" or "exhaustion" may have occurred, as described in
experimental infectious and autoimmune diseases.
Clinical and A-Gliadin Specific T Cell Responses with 3 and 10 Day
Bread Challenge
[0168] In a pilot study, two subjects with Coeliac disease in
remission, defined by absence of serum anti-endomysial antibody
(EMA), on a gluten free diet were fed four slices of standard
gluten-containing white bread daily in addition to their usual
gluten free diet. Subject 1 ceased bread because of abdominal pain,
mouth ulcers and mild diarrhoea after three days, but Subject 2
continued for 10 days with only mild nausea at one week. The EMA
became positive in Subject 2 one week after the bread challenge,
indicating the bread used had caused a relapse of Coeliac disease.
But in Subject 1, EMA remained negative up to two months after
bread challenge. In both subjects, symptoms that appeared with
bread challenge resolved within two days after returning to gluten
free diet.
[0169] PBMC responses in IFN.gamma. ELISPOT assays to A-gliadin
peptides were not found before or during bread challenge. But from
the day after bread withdrawal (Day 4) in Subject 1 a single pool
of 5 overlapping peptides spanning A-gliadin 51-85 (Pool 3) treated
with tTG showed potent IFNg responses (see FIG. 1a). In Subject 1,
the PBMC IFNg response to A-gliadin peptide remained targeted to
Pool 3 alone and was maximal on Day 8. The dynamics and magnitude
of the response to Pool 3 was similar to that elicited by
.alpha.-chymotrypsin digested gliadin. PBMC IFN.gamma. responses to
tTG-treated Pool 3 were consistently 5 to 12-fold greater than Pool
3 not treated with tTG, and responses to .alpha.-chymotrypsin
digested gliadin were 3 to 10-fold greater if treated with tTG. In
Subject 2, Pool 3 treated with tTG was also the only immunogenic
set of A-gliadin peptides on Day 8, but this response was weaker
than Subject 1, was not seen on Day 4 and by Day 11 the response to
Pool 3 had diminished and other tTG-treated pools of A-gliadin
peptides elicited stronger IFN.alpha. responses (see FIG. 1b).
[0170] The pilot study indicated that the initial T cell response
in these Coeliac disease subjects was against a single tTG-treated
A-gliadin pool of five peptides and was readily measured in
peripheral blood. But if antigen exposure is continued for ten days
instead of three, T cell responses to other A-gliadin peptides
appear, consistent with epitope spreading.
Coeliac Disease-Specific IFN-g Induction by tTG-Treated A-Gliadin
Peptides
[0171] In five out of six further Coeliac disease subjects on
gluten free diet (see Table 1), bread challenge for three days
identified tTG-treated peptides in Pool 3, and in particular,
peptides corresponding to 56-70 (12) and 60-75 (13) as the sole
A-gliadin components eliciting IFN.gamma. from PBMC (see FIG. 2).
IL-10 ELISPOT assays run in parallel to IFN.gamma. ELISPOT showed
no IL-10 response to tTG-treated peptides 12 or 13. In one subject,
there were no IFN.gamma. responses to any A-gliadin peptide or
.alpha.-chymotrypsin digested gliadin before, during or up to four
days after bread challenge. In none of these Coeliac disease
subjects did EMA status change from baseline when measured for up
to two months after bread challenge.
[0172] PBMC from four healthy, EMA-negative subjects with the
HLA-DQ alleles .alpha.1*0501, .beta.1*0201 (ages 28-52, 2 females)
who had been challenged for three days with bread after following a
gluten free diet for one month, showed no IFN.gamma. responses
above the negative control to any of the A-gliadin peptides with or
without tTG treatment. Thus, induction of IFN.gamma. in PBMC to
tTG-treated Pool 3 and A-gliadin peptides 56-70 (12) and 60-75 (13)
were Coeliac disease specific (7/8 vs 0/4, p<0.01 by Chi-squared
analysis).
Fine Mapping of the Minimal A-Gliadin T Cell Epitope
[0173] tTG-treated peptides representing truncations of A-gliadin
56-75 revealed that the same core peptide sequence (QPQLP) was
essential for antigenicity in all of the five Coeliac disease
subjects assessed (see FIG. 3). PBMC IFN.gamma. responses to
tTG-treated peptides spanning this core sequence beginning with the
7-mer PQPQLPY and increasing in length, indicated that the
tTG-treated 17-mer QLQPFPQPQLPYPQPQS (A-gliadin 57-73) possessed
optimal activity in the IFN.gamma. ELISPOT (see FIG. 4).
Deamidation of Q65 by tTG Generates the Immunodominant T Cell
Epitope in A-Gliadin
[0174] HPLC analysis demonstrated that tTG treatment of A-gliadin
56-75 generated a single product that eluted marginally later than
the parent peptide. Amino acid sequencing indicated that out of the
six glutamine (Q) residues contained in A-gliadin 56-75, Q65 was
preferentially deamidated by tTG (see FIG. 5). Bioactivity of
peptides corresponding to serial expansions from the core A-gliadin
62-68 sequence in which glutamate (E) replaced Q65, was equivalent
to the same peptides with Q65 after tTG-treatment (see FIG. 4a).
Replacement of Q57 and Q72 by E together or alone, with E65 did not
enhance antigenicity of the 17-mer in the three Coeliac disease
subjects studied (see FIG. 6). Q57 and Q72 were investigated
because glutamine residues followed by proline in gliadin peptides
are not deamidated by tTG in vitro (W. Vader et al, Proceedings 8th
International Symposium Coeliac Disease). Therefore, the
immunodominant T cell epitope was defined as QLQPFPQPELPYPQPQS.
Immunodominant T Cell Epitope Response is DQ2-Restricted and CD4
Dependent
[0175] In two Coeliac disease subjects homozygous for HLA-DQ
.alpha.1*0501, .beta.1*0201, anti-DQ monoclonal antibody blocked
the ELISPOT IFN.gamma. response to tTG-treated A-gliadin 56-75, but
anti-DP and -DR antibody did not (see FIG. 7). Anti-CD4 and
anti-CD8 magnetic bead depletion of PBMC from two Coeliac disease
subjects indicated the IFN.gamma. response to tTG-treated A-gliadin
56-75 is CD4 T cell-mediated.
Discussion
[0176] In this study we describe a rather simple dietary antigen
challenge using standard white bread to elicit a transient
population of CD4 T cells in peripheral blood of Coeliac disease
subjects responsive to a tTG-treated A-gliadin 17-mer with the
sequence: QLQPFPQPELPYPQPQS (residues 57-73). The immune response
to A-gliadin 56-75 (Q.fwdarw.E65) is restricted to the Coeliac
disease-associated HLA allele, DQ .alpha.1*0501, .beta.1*0201.
Tissue transglutaminase action in vitro selectively deamidates Q65.
Elicited peripheral blood IFNg responses to synthetic A-gliadin
peptides with the substitution Q.fwdarw.E65 is equivalent to
tTG-treated Q65 A-gliadin peptides; both stimulate up to 10-fold
more T cells in the IFNg ELISPOT than unmodified Q65 A-gliadin
peptides.
[0177] We have deliberately defined this Coeliac disease-specific T
cell epitope using in vivo antigen challenge and short-term ex vivo
immune assays to avoid the possibility of methodological artifacts
that may occur with the use of T cell clones in epitope mapping.
Our findings indicate that peripheral blood T cell responses to
ingestion of gluten are rapid but short-lived and can be utilized
for epitope mapping. In vivo antigen challenge has also shown there
is a temporal hierarchy of immune responses to A-gliadin peptides;
A-gliadin 57-73 modified by tTG not only elicits the strongest IFNg
response in PBMC but it is also the first IFNg response to
appear.
[0178] Because we have assessed only peptides spanning A-gliadin,
there may be other epitopes in other gliadins of equal or greater
importance in the pathogenesis of Coeliac disease. Indeed, the
peptide sequence at the core of the epitope in A-gliadin that we
have identified (PQPQLPY) is shared by several other gliadins
(SwissProt and Trembl accession numbers: P02863, Q41528, Q41531,
Q41533, Q9ZP09, P04722, P04724, P18573). However, A-gliadin
peptides that have previously been shown to possess bioactivity in
biopsy challenge and in vivo studies (for example: 31-43, 44-55,
and 206-217).sup.4,5 did not elicit IFNg responses in PBMC
following three day bread challenge in Coeliac disease subjects.
These peptides may be "secondary" T cell epitopes that arise with
spreading of the immune response.
Example 2
The Effect on T Cell Recognition of Substitutions in the
Immunodominant Epitope
[0179] The effect of substituting the glutamate at position 65 in
the 57-73 A-gliadin epitope was determined by measuring peripheral
blood responses against the substituted epitopes in an IFN.gamma.
ELISPOT assay using synthetic peptides (at 50 .mu.g/ml). The
responses were measured in 3 Coeliac disease subjects 6 days after
commencing gluten challenge (4 slices bread daily for 3 days).
Results are shown in table 3 and FIG. 8. As can be seen
substitution of the glutamate to histidine, tyrosine, tryptophan,
lysine, proline or arginine stimulated a response whose magnitude
was less than 10% of the magnitude of the response to the
immunodominant epitope. Thus mutation of A-gliadin at this position
could be used to produce a mutant gliadin with reduce or absent
immunoreactivity.
Example 3
Testing the Immunoreactivity of Equivalent Peptides from Other
Naturally Occurring Gliadins
[0180] The immunoreactivity of equivalent peptides form other
naturally occurring wheat gliadins was assessed using synthetic
peptides corresponding to the naturally occurring sequences which
were then treated with transglutaminase. These peptides were tested
in an ELISPOT in the same manner and with PBMCs from the same
subjects as described in Example 2. At least five of the peptides
show immunoreactivity comparable to the A-gliadin 57-73 E65 peptide
(after transglutaminase treatment) indicating that other gliadin
proteins in wheat are also likely to induce this Coeliac
disease-specific immune response (Table 4 and FIG. 9).
Methods
[0181] Subjects: Patients used in the study attended a Coeliac
Clinic in Oxford, United Kingdom. Coeliac disease was diagnosed on
the basis of typical small intestinal histology, and normalization
of symptoms and small intestinal histology with gluten free
diet.
Tissue typing: Tissue typing was performed using DNA extracted from
EDTA-anticoagulated peripheral blood. HLA-DQA and DQB genotyping
was performed by PCR using sequence-specific primer
mixes.sup.6-8.
[0182] Anti-endomysial antibody assay: EMA were detected by
indirect immunofluorescence using patient serum diluted 1:5 with
monkey oesophagus, followed by FITC-conjugated goat anti-human IgA.
IgA was quantitated prior to EMA, none of the subjects were IgA
deficient.
[0183] Antigen Challenge: Coeliac disease subjects following a
gluten free diet, consumed 4 slices of gluten-containing bread (50
g/slice, Sainsbury's "standard white sandwich bread") daily for 3
or 10 days. EMA was assessed the week before and up to two months
after commencing the bread challenge. Healthy subjects who had
followed a gluten free diet for four weeks, consumed their usual
diet including four slices of gluten-containing bread for three
days, then returned to gluten free diet for a further six days.
[0184] IFN.gamma. and IL-10 ELISPOT: PBMC were prepared from 50-100
ml of venous blood by Ficoll-Hypaque density centrifugation. After
three washes, PBMC were resuspended in complete RPMI containing 10%
heat inactivated human AB serum. ELISPOT assays for single cell
secretion of IFN.gamma. and IL-10 were performed using commercial
kits (Mabtech; Stockholm, Sweden) with 96-well plates (MAIP-S-45;
Millipore, Bedford, Mass.) according to the manufacturers
instructions (as described elsewhere.sup.9) with 2-5.times.10.sup.5
(IFN.gamma.) or 0.4-1.times.10.sup.5 (IL-10) PBMC in each well.
Peptides were assessed in duplicate wells, and Mycobacterium
tuberculosis purified protein derivative (PPD RT49) (Serum
Institute; Copenhagen, Denmark) (20 .mu.g/ml) was included as a
positive control in all assays.
[0185] Peptides: Synthetic peptides were purchased from Research
Genetics (Huntsville, Ala.) Mass-spectroscopy and HPLC verified
peptides' authenticity and >70% purity. Digestion of gliadin
(Sigma; G-3375) (100 mg/ml) with .alpha.-chymotrypsin (Sigma;
C-3142) 200:1 (w/w) was performed at room temperature in 0.1 M
NH.sub.4HCO.sub.3 with 2M urea and was halted after 24 h by heating
to 98.degree. C. for 10 minutes. After centrifugation (13 000 g, 10
minutes), the gliadin digest supernatant was filter-sterilized (0.2
mm). Digestion of gliadin was verified by SDS-PAGE and protein
concentration assessed. .alpha.-Chymotrypsin-digested gliadin (640
.mu.g/ml) and synthetic gliadin peptides (15-mers: 160 .mu.g/ml,
other peptides: 0.1 mM) were individually treated with tTG (Sigma;
T-5398) (50 .mu.g/ml) in PBS+CaCl.sub.2 1 mM for 2 h at 37.degree.
C. Peptides and peptide pools were aliquoted into sterile 96-well
plates and stored frozen at -20.degree. C. until use.
[0186] Amino acid sequencing of peptides: Reverse phase HPLC was
used to purify the peptide resulting from tTG treatment of
A-gliadin 56-75. A single product was identified and subjected to
amino acid sequencing (automated sequencer Model 494A, Applied
Biosystems, Foster City, Calif.). The sequence of unmodified G56-75
was confirmed as: LQLQPFPQPQLPYPQPQSFP, and tTG treated G56-75 was
identified as: LQLQPFPQPELPYPQPQSFP. Deamidation of glutamyl
residues was defined as the amount (pmol) of glutamate recovered
expressed as a percent of the combined amount of glutamine and
glutamate recovered in cycles 2, 4, 8, 10, 15 and 17 of the amino
acid sequencing. Deamidation attributable to tTG was defined as (%
deamidation of glutamine in the tTG treated peptide-% deamidation
in the untreated peptide)/(100-% deamidation in the untreated
peptide).
[0187] CD4/CD8 and HLA Class II Restriction: Anti-CD4 or anti-CD8
coated magnetic beads (Dynal, Oslo, Norway) were washed four times
with RPMI then incubated with PBMC in complete RPMI containing 10%
heat inactivated human AB serum (5.times.10.sup.6 cells/ml) for 30
minutes on ice. Beads were removed using a magnet and cells
remaining counted. In vivo HLA-class II restriction of the immune
response to tTG-treated A-gliadin 56-75 was established by
incubating PBMC (5.times.10.sup.6 cells/ml) with anti-HLA-DR
(L243), -DQ (L2), and -DP (B7.21) monoclonal antibodies (10
.mu.g/ml) at room temperature for one hour prior to the addition of
peptide.
Example 4
Mucosal Integrin Expression by Gliadin-Specific Peripheral Blood
Lymphocytes
[0188] Interaction between endothelial and lymphocyte adressins
facilitates homing of organ-specific lymphocytes. Many adressins
are known. The heterodimer .alpha..sub.4.beta..sub.7 is specific
for lamina propria gut and other mucosal lymphocytes, and
.alpha..sup.E.beta..sub.7 is specific and intra-epithelial
lymphocytes in the gut and skin. Approximately 30% of peripheral
blood CD4 T cells express .alpha..sub.4.beta..sub.7 and are
presumed to be in transit to a mucosal site, while 5% of peripheral
blood T cells express .alpha..sup.E.beta..sub.7. Immunomagnetic
beads coated with antibody specific for .alpha..sup.E or
.beta..sub.7 deplete PBMC of cells expressing
.alpha..sup.E.beta..sub.7 or .alpha..sup.E.beta..sub.7 and
.alpha..sub.4.beta..sub.7, respectively. In combination with
ELISpot assay, immunomagnetic bead depletion allows determination
of gliadin-specific T cell addressin expression that may identify
these cells as homing to a mucosal surface. Interestingly, gluten
challenge in vivo is associated with rapid influx of CD4T cells to
the small intestinal lamina propria (not intra-epithelial sites),
where over 90% lymphocytes express .alpha..sub.4.beta..sub.7.
[0189] Immunomagnetic beads were prepared and used to deplete PBMC
from coeliac subjects on day 6 or 7 after commencing 3 day gluten
challenge. FACS analysis demonstrated .alpha..sup.E beads depleted
approximately 50% of positive CD4 T cells, while .beta..sub.7 beads
depleted all .beta..sub.7 positive CD4 T cells. Depletion of PBMC
using CD4- or .beta..sub.7-beads, but not CD8- or
.alpha..sup.E-beads, abolished responses in the interferon gamma
ELISpot. tTG gliadin and PPD responses were abolished by CD4
depletion, but consistently affected by integrin-specific bead
depletion.
[0190] Thus A-gliadin 57-73 QE65-specific T cells induced after
gluten challenge in coeliac disease express the integrin,
.alpha..sub.4.beta..sub.7, present on lamina propria CD4 T cells in
the small intestine.
Example 5
Optimal T Cell Epitope Length
[0191] Previous data testing peptides from 7 to 17 aminoacids in
length spanning the core of the dominant T cell epitope in
A-gliadin indicated that the 17mer, A-gliadin 57-73 QE65 induced
maximal responses in the interferon gamma Elispot using peripheral
blood mononuclear cells (PBMC) from coeliac volunteers 6 days after
commencing a 3-day gluten challenge.
[0192] Peptides representing expansions form the core sequence of
the dominant T cell epitope in A-gliadin were assessed in the IFN
gamma ELISPOT using peripheral blood mononuclear cells (PBMC) from
coeliac volunteers in 6 days after commencing a 3-day gluten
challenge (n=4). Peptide 13: A-gliadin 59-71 QE65 (13mer), peptide
15: 58-72 QE65 (15mer), . . . , peptide 27: 52-78 QE65 (27mer).
[0193] As shown in FIG. 11 expansion of the A-gliadin 57-73 QE65
sequence does not substantially enhance response in the IFNgamma
Elispot. Subsequent Examples characterise the agonist and
antagonist activity of A-gliadin 57-73 QE65 using 17mer
peptides.
Example 6
Comparison of A-Gliadin 57-73 QE65 with Other DQ2-Restricted T Cell
Epitopes in Coeliac Disease
[0194] Dose response studies were performed using peptides
corresponding to unmodified and transglutaminase-treated peptides
corresponding to T cell epitopes of gluten-specific T cell clones
and lines from intestinal biopsies of coeliac subjects. Responses
to peptides were expressed as percent of response to A-gliadin
57-73 QE65. All subjects were HLA-DQ2+ (none were DQ8+).
[0195] The studies indicate that A-gliadin 57-73 QE65 is the most
potent gliadin peptide for induction of interferon gamma in the
ELISpot assay using coeliac PBMC after gluten challenge (see FIG.
12a-h, and Tables 5 and 6). The second and third epitopes are
suboptimal fragments of larger peptides i.e. A-gliadin 57-73 QE65
and GDA4_WHEAT P04724-84-100 QE92. The epitope is only modestly
bioactive (approximately 1/20.sup.th as active as A-gliadin 57-73
QE65 after blank is subtracted).
[0196] A-gliadin 57-73 QE65 is more potent than other known T cell
epitopes in coeliac disease. There are 16 polymorphisms of
A-gliadin 57-73 (including the sequence PQLPY) amongst sequenced
gliadin genes, their bioactivity is assessed next.
Example 7
Comparison of Gliadin- and A-Gliadin 57-73 QE65-Specific Responses
in Peripheral Blood
[0197] The relative contribution of the dominant epitope, A-gliadin
57-73 QE65, to the total T cell response to gliadin in coeliac
disease is a critical issue. Pepsin-trypsin and
chymotrypsin-digested gliadin have been traditionally used as
antigen for development of T cell lines and clones in coeliac
disease. However, it is possible that these proteases may cleave
through certain peptide epitopes. Indeed, chymotrypsin digestion of
recombinant .alpha.9-gliadin generates the peptide QLQPFPQPELPY,
that is a truncation of the optimal epitope sequence
QLQPFPQPELPYPQPQS (see above). Transglutaminase-treatment
substantially increases the potency of chymotrypsin-digested
gliadin in proliferation assays of gliadin-specific T cell clones
and lines. Hence, transglutaminase-treated chymotrypsin-digested
gliadin (tTG gliadin) may not be an ideal antigen, but responses
against this mixture may approximate the "total" number of
peripheral blood lymphocyte specific for gliadin. Comparison of
responses against A-gliadin 57-73 QE65 and tTG gliadin in the
ELISpot assay gives an indication of the contribution of this
dominant epitope to the overall immune response to gliadin in
coeliac disease, and also be a measure of epitope spreading.
[0198] PBMC collected on day 6 or 7 after commencing gluten
challenge in 4 coeliac subjects were assessed in dose response
studies using chymotrypsin-digested gliadin+/-tTG treatment and
compared with ELISpot responses to an optimal concentration of
A-gliadin 57-73 QE65 (25 mcg/ml). TTG treatment of gliadin enhanced
PBMC responses in the ELISpot approximately 10-fold (tTG was
comparable to blank when assessed alone) (see FIG. 13a-c). In the
four coeliac subjects studied, A-gliadin 57-73 QE65 (25 mcg/ml)
elicited responses between 14 and 115% those of tTG gliadin (500
mcg/ml), and the greater the response to A-gliadin 57-73 QE65 the
greater proportion it represented of the tTG gliadin response.
[0199] Relatively limited data suggest that A-gliadin 57-73 QE65
responses are comparable to tTG gliadin in some subjects. Epitope
spreading associated with more evolved anti-gliadin T cell
responses may account for the smaller contribution of A-gliadin
57-73 QE65 to "total" gliadin responses in peripheral blood in some
individuals. Epitope spreading may be maintained in individuals
with less strictly gluten free diets.
Example 8
Definition of Gliadin Peptides Bioactive in Coeliac Disease
Polymorphisms of A-Gliadin 57-73
[0200] Overlapping 15mer peptides spanning the complete sequence of
A-gliadin were assessed in order to identify the immunodominant
sequence in coeliac disease. A-gliadin was the first fully
sequenced alpha gliadin protein and gene, but is one of
approximately 30-50 related alpha gliadin proteins in wheat. Twenty
five distinct alpha-gliadin genes have been identified by searching
protein data bases, Swiss-Prot and TREMBL describing a further 8
alpha-gliadins. Contained within these 25 alpha-gliadins, there are
16 distinct polymorphisms of the sequence corresponding to
A-gliadin 57-73 (see Table 7).
[0201] Synthetic peptides corresponding to these 16 polymorphisms,
in an unmodified form, after treatment with transglutaminase in
vitro, as well as with glutamate substituted at position 10
(equivalent to QE65 in A-gliadin 57-73) were assessed using PBMC
from coeliac subjects, normally following a gluten free diet, day 6
or 7 after gluten challenge in interferon gamma ELISpot assays.
Glutamate-substituted peptides were compared at three
concentrations (2.5, 25 and 250 mcg/ml), unmodified peptide and
transglutaminase-treated peptides were assessed at 25 mcg/ml only.
Bioactivity was expressed as % of response associated with
A-gliadin 57-73 QE65 25 mcg/ml in individual subjects (n=4). (See
FIG. 14).
[0202] Bioactivity of "wild-type" peptides was substantially
increased (>5-fold) by treatment with transglutaminase.
Transglutaminase treatment of wild-type peptides resulted in
bioactivity similar to that of the same peptides substituted with
glutamate at position 10. Bioactivities of five
glutamate-substituted peptides (B, C, K, L, M), were >70% that
of A-gliadin 57-73 QE65 (A), but none was significantly more
bioactive than A-gliadin 57-73 QE65. PBMC responses to
glutamate-substituted peptides at concentrations of 2.5 and 250
mcg/ml were comparable to those at 25 mcg/ml. Six
glutamate-substituted gliadin peptides (H, I, J, N, O P) were
<15% as bioactive as A-gliadin 57-73 QE65. Other peptides were
intermediate in bioactivity.
[0203] At least six gliadin-derived peptides are equivalent in
potency to A-gliadin 57-73 QE65 after modification by
transglutaminase. Relatively non-bioactive polymorphisms of
A-gliadin 57-73 also exist. These data indicate that
transglutaminase modification of peptides from several gliadins of
Tricetum aestivum, T. uartu and T. spelta may be capable of
generating the immunodominant T cell epitope in coeliac
disease.
[0204] Genetic modification of wheat to generate non-coeliac-toxic
wheat is likely require removal or modification of multiple gliadin
genes. Generation of wheat containing gliadins or other proteins or
peptides incorporating sequences defining altered peptide ligand
antagonists of A-gliadin 57-73 is an alternative strategy to
generate genetically modified wheat that is therapeutic rather than
"non-toxic" in coeliac disease.
Example 9
Definition of Core Epitope Sequence
[0205] Comparison of peptides corresponding to truncations of
A-gliadin 56-75 from the N- and C-terminal indicated that the core
sequence of the T cell epitope is PELPY (A-gliadin 64-68). Attempts
to define non-agonists and antagonists will focus on variants of
A-gliadin that are substituted at residues that substantially
contribute to its bioactivity.
[0206] Peptides corresponding to A-gliadin 57-73 QE65 with alanine
(FIG. 15) or lysine (FIG. 16) substituted for residues 57 to 73
were compared in the IFN gamma ELISPOT using peripheral blood
mononuclear cells (PBMC) from coeliac volunteers 6 days after
commencing a 3-day gluten challenge (n=8). [BL is blank, E is
A-gliadin 57-73 QE65: QLQPFPQPELPYPQPQS].
[0207] It was found that residues corresponding to A-gliadin 60-70
QE65 (PFPQPELPYPQ) contribute substantially to the bioactivity in
A-gliadin 57-73 QE65. Variants of A-gliadin 57-73 QE65 substituted
at positions 60-70 are assessed in a 2-step procedure. Initially,
A-gliadin 57-73 QE65 substituted at positions 60-70 using 10
different aminoacids with contrasting properties are assessed. A
second group of A-gliadin 57-73 QE65 variants (substituted with all
other naturally occurring aminoacids except cysteine at positions
that prove are sensitive to modification) are assessed in a second
round.
Example 10
Agonist Activity of Substituted Variants of A-Gliadin 57-73
QE65
[0208] A-gliadin 60-70 QE65 is the core sequence of the dominant T
cell epitope in A-gliadin. Antagonist and non-agonist peptide
variants of this epitope are most likely generated by modification
of this core sequence. Initially, A-gliadin 57-73 QE65 substituted
at positions 60-70 using 10 different aminoacids with contrasting
properties will be assessed in the IFNgamma ELISPOT using PBMC from
coeliac subjects 6 days after starting 3 day gluten challenge. A
second group of A-gliadin 57-73 QE65 variants (substituted with all
other naturally occurring aminoacids except cysteine) at positions
61-70 were also assessed. Both groups of peptides (all at 50
mcg/ml, in duplicate) were assessed using PBMC from 8 subjects and
compared to the unmodified peptide (20 replicates per assay).
Previous studies indicate that the optimal concentration for
A-gliadin 57-73 QE65 in this assay is between 10 and 100
mcg/ml.
[0209] Results are expressed as mean response in spot forming cells
(95% confidence interval) as % A-G 57-73 QE65 mean response in each
individual. Unpaired t-tests will be used to compare ELISPOT
responses of modified peptides with A-G 57-73 QE65. Super-agonists
were defined as having a greater response than A-G 57-73 QE65 at a
level of significance of p<0.01; partial agonists as having a
response less than A-G 57-73 QE65 at a level of significance of
p<0.01, and non-agonists as being not significantly different
(p>0.01) from blank (buffer without peptide). Peptides with
agonist activity 30% or less that of A-gliadin 57-73 QE65 were
considered "suitable" partial or non-agonists to assess for
antagonistic activity (see Table 8 and FIGS. 17-27).
[0210] The IFNgamma ELISPOT response of PBMC to A-gliadin 57-73
QE65 is highly specific at a molecular level. Proline at position
64 (P64), glutamate at 65 (E65) and leucine at position 66 (L66),
and to a lesser extent Q63, P67, Y68 and P69 are particularly
sensitive to modification. The substitutions Y61 and Y70 both
generate super-agonists with 30% greater bioactivity than the
parent peptide, probably by enhancing binding to HLA-DQ2 since the
motif for this HLA molecule indicates a preference for bulky
hydrophobic resides at positions 1 and 9. Eighteen non-agonist
peptides were identified. Bioactivities of the variants (50
mcg/ml): P65, K64, K65 and Y65 (bioactivity 7-8%) were comparable
to blank (7%). In total, 57 mutated variants of A-gliadin 57-73
QE65 were 30% or less bioactive than A-gliadin 57-73 QE65.
[0211] The molecular specificity of the peripheral blood lymphocyte
(PBL) T cell response to the dominant epitope, A-gliadin 57-73
QE65, is consistently reproducible amongst HLA-DQ2+ coeliac
subjects, and is highly specific to a restricted number of
aminoacids in the core 7 aminoacids. Certain single-aminoacid
variants of A-gliadin 57-73 QE65 are consistently non-agonists in
all HLA-DQ2+ coeliac subjects.
Example 11
Antagonist Activity of Substituted Variants
[0212] The homogeneity of the PBL T cell response to A-gliadin
57-73 QE65 in HLA-DQ2+ coeliac disease suggests that altered
peptide ligands (APL) capable of antagonism in PBMC ex vivo may
exist, even though the PBL T cell response is likely to be poly- or
oligo-clonal. APL antagonists are generally weak agonists.
Fifty-seven single aminoacid-substituted variants of A-gliadin
57-73 QE65 with agonist activity 30% or less have been identified
and are suitable candidates as APL antagonists. In addition,
certain weakly bioactive naturally occurring polymorphisms of
A-gliadin 57-73 QE65 have also been identified (see below) and may
be "naturally occurring" APL antagonists. It has also been
suggested that competition for binding MHC may also antagonise
antigen-specific T cell immune. Hence, non-gliadin peptides that do
not induce IFNgamma responses in coeliac PBMC after gluten
challenge but are known to bind to HLA-DQ2 may be capable of
reducing T cell responses elicited by A-gliadin 57-73 QE65. Two
peptides that bind avidly to HLA-DQ2 are HLA class 1.alpha. 46-60
(HLA 1a) (PRAPWIEQEGPEYW) and thyroid peroxidase (tp) 632-645Y
(IDVWLGGLLAENFLPY).
[0213] Simultaneous addition of peptide (50 .mu.g/ml) or buffer and
A-gliadin 57-73 QE65 (10 .mu.g/ml) in IFNgamma ELISPOT using PBMC
from coeliac volunteers 6 days after commencing 3 day gluten
challenge (n=5). Results were expressed as response with peptide
plus A-G 57-73 QE65 (mean of duplicates) as % response with buffer
plus A-G 57-73 QE65 (mean of 20 replicates). (See Table 9).
[0214] Four single aminoacid-substituted variants of A-gliadin
57-73 QE65 reduce the interferon gamma PBMC ELISPOT response to
A-gliadin 57-73 QE65 (p<0.01) by between 25% and 28%, 13 other
peptide variants reduce the ELISPOT response by between 18% and 24%
(p<0.06). The HLA-DQ2 binder, thyroid peroxidase (tp) 632-645Y
reduces PBMC interferon gamma responses to A-gliadin 57-73 QE65 by
31% (p<0.0001) but the other HLA-DQ2 binder, HLA class 1 .alpha.
46-60, does not alter responses (see Table 9). The peptide
corresponding to a transglutaminase-modified polymorphism of
A-gliadin 57-73, SwissProt accession no.: P04725 82-98 QE90
(PQPQPFPPELPYPQPQS) reduces responses to A-gliadin 57-73 QE65 by
19% (p<0.009) (see Table 11).
[0215] Interferon gamma responses of PBMC to A-gliadin 57-73 QE65
in ELISPOT assays are reduced by co-administration of certain
single-aminoacid A-gliadin 57-73 QE65 variants, a polymorphism of
A-gliadin 57-73 QE65, and an unrelated peptide known to bind
HLA-DQ2 in five-fold excess. These finding suggest that altered
peptide ligand antagonists of A-gliadin 57-73 QE65 exist. Not only
putative APL antagonists but also certain peptides that bind
HLA-DQ2 effectively reduce PBL T cell responses to A-gliadin 57-73
QE65.
[0216] These findings support two strategies to interrupt the T
cell response to the dominant A-gliadin epitope in HLA-DQ2+ coeliac
disease. [0217] 1. Optimisation of APL antagonists by substituting
aminoacids at more than one position (64-67) for use as
"traditional" peptide pharmaceuticals or for specific genetic
modification of gliadin genes in wheat. [0218] 2. Use of high
affinity HLA-DQ2 binding peptides to competitively inhibit
presentation of A-gliadin 57-73 QE65 in association with HLA-DQ2.
[0219] These two approaches may be mutually compatible.
Super-agonists were generated by replacing F61 and Q70 with
tyrosine residues. It is likely these super-agonists resulted from
improved binding to HLA-DQ2 rather than enhanced contact with the T
cell receptor. By combining these modifications with other
substitutions that generate modestly effective APL antagonists
might substantially enhance the inhibitory effect of substituted
A-gliadin 57-73 QE65 variants.
Example 12
Development of Interferon Gamma ELISpot Using PBMC and A-Gliadin
57-73 QE65 and P04724 84-100 QE92 as a Diagnostic for Coeliac
Disease
Definition of Immune-Responsiveness in Newly Diagnosed Coeliac
Disease
[0220] Induction of responsiveness to the dominant A-gliadin T cell
epitope in PBMC measured in the interferon gamma ELISpot follows
gluten challenge in almost all DQ2+ coeliac subjects following a
long term strict gluten free diet (GFD) but not in healthy DQ2+
subjects after 4 weeks following a strict GFD. A-gliadin 57-73 QE65
responses are not measurable in PBMC of coeliac subjects before
gluten challenge and pilot data have suggested these responses
could not be measured in PBMC of untreated coeliacs. These data
suggest that in coeliac disease immune-responsiveness to A-gliadin
57-73 QE65 is restored following antigen exclusion (GFD). If a
diagnostic test is to be developed using the ELISpot assay and
PBMC, it is desirable to define the duration of GFD required before
gluten challenge is capable of inducing responses to A-gliadin
57-73 QE65 and other immunoreactive gliadin peptides in blood.
[0221] Newly diagnosed DQ2+ coeliac subjects were recruited from
the gastroenterology outpatient service. PBMC were prepared and
tested in interferon gamma ELISpot assays before subjects commenced
GFD, and at one or two weeks after commencing GFD. In addition,
gluten challenge (3 days consuming 4 slices standard white bread,
200 g/day) was performed at one or two weeks after starting GFD.
PBMC were prepared and assayed on day six are after commencing
gluten challenge. A-gliadin 57-73 QE65 (A), P04724 84-100 QE92 (B)
(alone and combined) and A-gliadin 57-73 QP65 (P65) (non-bioactive
variant, see above) (all 25 mcg/ml) were assessed.
[0222] All but one newly diagnosed coeliac patient was DQ2+ (one
was DQ8+) (n-=11). PBMC from newly diagnosed coeliacs that were
untreated, or after 1 or 2 weeks following GFD did not show
responses to A-gliadin 57-73 QE65 and P04724 84-100 QE92 (alone or
combined) that were not significantly different from blank or
A-gliadin 57-73 QP65 (n=9) (see FIG. 28). Gluten challenge in
coeliacs who had followed GFD for only one week did not
substantially enhance responses to A-gliadin 57-73 QE65 or P04724
84-100 QE92 (alone or combined). But gluten challenge 2 weeks after
commencing GFD did induce responses to A-gliadin 57-73 QE65 and
P04724 84-100 QE92 (alone or combined) that were significantly
greater than the non-bioactive variant A-gliadin 57-73 QP65 and
blank. Although these responses after gluten challenge at 2 weeks
were substantial they appear to be less than in subjects >2
months after commencing GFD. Responses to A-gliadin 57-73 QE65
alone were equivalent or greater than responses to P04724 84-100
QE92 alone or when mixed with A-gliadin 57-73 QE65. None of the
subjects experienced troubling symptoms with gluten challenge.
[0223] Immune responsiveness (as measured in PBMC after gluten
challenge) to A-gliadin is partially restored 2 weeks after
commencing GFD, implying that "immune unresponsiveness" to this
dominant T cell epitope prevails in untreated coeliac disease and
for at least one week after starting GFD. The optimal timing of a
diagnostic test for coeliac disease using gluten challenge and
measurement of responses to A-gliadin 57-73 QE65 in the ELISpot
assay is at least 2 weeks after commencing a GFD.
[0224] Interferon gamma-secreting T cells specific to A-gliadin
57-73 QE65 cannot be measured in the peripheral blood in untreated
coeliacs, and can only be induced by gluten challenge after at
least 2 weeks GFD (antigen exclusion). Therefore, timing of a
diagnostic test using this methodology is crucial and further
studies are needed for its optimization. These finding are
consistent with functional anergy of T cells specific for the
dominant epitope, A-gliadin 57-73 QE65, reversed by antigen
exclusion (GFD). This phenomenon has not been previously
demonstrated in a human disease, and supports the possibility that
T cell anergy may be inducible with peptide therapy in coeliac
disease.
REFERENCES
[0225] 1. Molberg O, et al. Nature Med. 4, 713-717 (1998). [0226]
2. Quarsten H, et al. Eur. J. Immunol. 29, 2506-2514 (1999). [0227]
3. Greenberg C S et al. FASEB 5, 3071-3077 (1991). [0228] 4.
Mantzaris G, Jewell D. Scand. J. Gastroenterol. 26, 392-398 (1991).
[0229] 5. Mauri L, et al. Scand. J. Gastroenterol. 31, 247-253
(1996). [0230] 6. Bunce M, et al. Tissue Antigens 46, 355-367
(1995). [0231] 7. Olerup O, et al. Tissue antigens 41, 119-134
(1993). [0232] 8. Mullighan C G, et al. Tissue-Antigens. 50, 688-92
(1997).
[0233] 9. Plebanski M et al. Eur. J. Immunol. 28, 4345-4355 (1998).
TABLE-US-00002 TABLE 1 A-Gliadin protein sequence (based on amino
acid sequencing) VRVPVPQLQP QNPSQQQPQE QVPLVQQQQF PGQQQQFPPQ
QPYPQPQIPFP SQQPYLQLQP FPQPQLPYPQ 1 11 21 31 41 51 61 PQSFPPQQPY
PQPQPQYSQP QQPISQQQAQ QQQQQQQQQQ QQQILQQILQ QQLIPCMDVV LQQHNIAHAR
71 81 91 101 111 121 131 SQVLQQSTYQ LLQELCCQHL WQIPEQSQCQ
AIHNVVHAII LHQQQKQQQQ PSSQVSFQQP LQQYPLGQGS 141 151 161 171 181 191
201 FRPSQQNPQA QGSVQPQQLP QFEEIRINLAL QTLPAMCNVY IAPYCTIAPF GIFGTN
211 221 231 241 251 261
[0234] TABLE-US-00003 TABLE 2 Coeliac disease subjects studied Age
Gluten Bread Symptoms Sex free diet HLA-DQ2 challenge with bread 1
64 f 14 yr Homozygote 3 days Abdominal pain, lethargy, mouth
ulcers, diarrhoea 2 57 m 1 yr Heterozygote 10 days Lethargy, nausea
3 35 f 7 yr Heterozygote 3 days Nausea 4 36 m 6 wk Homozygote 3
days Abdominal pain, mouth ulcers, diarrhoea 5 26 m 19 yr
Heterozygote 3 days None 6 58 m 35 yr Heterozygote 3 days None 7 55
m 1 yr Heterozygote 3 days Diarrhoea 8 48 f 15 yr Homozygote 3 days
Abdominal pain, diarrhoea
[0235] TABLE-US-00004 TABLE 3 Aminoacid at position 65 Range Mean
Glutamate (100) 100% Asparagine (50-84) 70% Aspartate (50-94) 65%
Alanine (44-76) 64% Cysteine (45-83) 62% Serine (45-75) 62% Valine
(24-79) 56% Threonine (46-66) 55% Glycine (34-47) 40% Leucine
(8-46) 33% Glutamine (16-21) 19% Isoleucine (3-25) 14% Methionine
(3-32) 14% Phenylalanine (0-33) 12% Histidine (0-13) 8% Tyrosine
(0-17) 8% Tryptophan (0-17) 8% Lysine (0-11) 4% Proline (0-4) 2%
Arginine (0-2) 1%
[0236] TABLE-US-00005 TABLE 4 Corresponding residues in glia-
Elisopt response din protein sequences (Acces- No TG TG Peptide
sequence sion no.) 8(1-13) QLQPFPQPQLPYPQPQS 57-73 .alpha.-Gliadin
(T. aestivum) Q41545 100(100) QLQPFPQPELPYPQPQS 57-73
.alpha.-Gliadin (T. aestivum) Q41545 5(1-7) 53(44-67)
QLQPFPQPQLPYSQPQP 77-93 .alpha./.beta.-Gliadin precursor (Tricetum.
aestivum) P02863 76-92 .alpha.-Gliadin (T. aestivum) Q41528 77-93
.alpha.-Gliadin storage protein (T. aestivum) Q41531 57-73
(.alpha./.beta.-Gliadin mature peptide (T. aestivum) Q41533 77-93
.alpha.-Gliadin precursor (T. spelta) Q9ZPO9 12(0-20) 83(61-113)
QLQPFPQPQLPYPQPQP 77-93 .alpha./.beta.-G1iadin A-II precursor (T.
aestivum) P0472 19(0-33) 83(74-97) QLQPFPQPQLPYPQPQL 77-93
.alpha./.beta.-Gliadin A-IV precursor (T. aestivum) P04724 77-93
.alpha./.beta.-Gliadin MMI precursor (T. aestivum) P18573 3(0-7)
109(41-152) PQLPYPQPQLPYPQPQP 84-100 .alpha./.beta.-Gliadin A-IV
precursor (T. aestivum) P04724 ND PQLPYPQPQLPYPQPQL 84-100
.alpha./.beta.-Gliadin MMI precursor (T. aestivum) P18573 0(0-1)
3(0-7) QLQPFLQPQLPYSQPQP 77-93 .alpha./.beta.-G1iadin A-I precursor
(T. aestivum) P04721 77-93 .alpha.-Gliadin (T. aestivum) Q41509
0(0-0) 2(0-7) QLQPFSQPQLPYSQPQP 77-93 .alpha.-Gliadin storage
protein (T. aestivum) Q41530 ND PQPQPFPPQLPYPQTQP 77-93
.alpha./.beta.-Gliadin A-III precursor (T. aestivum) P04723
17(0-40) 24(11-43) PQPQPFPPQLPYPQPQS 82-98 .alpha./.beta.-Gliadin
A-V precursor (T. aestivum) P04725 10(0-30) 19(11-33)
PQPQPFPPQLPYPQPPP 82-98 .alpha./.beta.-Gliadin clone PW1215
precursor (T. aestivum) P04726 82-98 .alpha./.beta.-Gliadin (T.
uratu) Q41632 10(0-30) 21(11-33) PQPQPFLPQLPYPQPQS 79-95
.alpha./.beta.-Gliadin clone PW8142 precursor (T. aestivum) P04726
79-95 .alpha.-Gliadin (T. aestivum) Q41529 79-95
.alpha./.beta.-Gliadin precursor (T. aestivum) Q41546
[0237] TABLE-US-00006 TABLE 5 T cell epitopes described in coeliac
disease Restric- Source tion Frequency Sequence* Gamma- DQ2 3/NS
(iTCC) QQLPQPEQPQQSFPEQERPF gliadin Alpha- DQ2 12/17 (iTCL)
QLQPFPQPELPY gliadin Alpha- DQ2 11/17 (iTCL) PQPELPYPQPELPY gliadin
Alpha- DQ2 1/23 (bTCC) LGQQQPFPPQQPYPQPQPF gliadin Alpha- DQ8 3/NS
(iTCC) QQYPSGEGSFQPSQENPQ gliadin Glutenin DQ8 1/1 (iTCC)
GQQGYYPTSPQQSGQ Alpha- DQ2 11/12 in QLQPFPQPELPYPQPQS gliadin vivo
NS not stated in original publication, iTCC intestinal T cell
clone, iTCL intestinal polyclonal T cell line, bTCC peripheral
blood T cell clone *All peptides are the products of
transglutaminase modifying wild type gluten peptides except the
fourth and sixth peptides
[0238] TABLE-US-00007 TABLE 6 Relative bioactivity of gliadin T
cell epitopes in coeliac PBMC after gluten challenge ELISpot
response as % A-gliadin 57-73 QE65 (all 25 mcg/ml) Wild Wild-
E-substi- Sequence* type type + tTG tuted QQLPQPEQPQQSFPEQERPF 9(3)
18(7) 10(5) QLQPFPQPELPY 6(2) 19(1) 8(3) PQPELPYPQPELPY 13(6) 53(8)
48(9) QQYPSGEGSFQPSQENPQ 10(3) 9(3) 14(8) QLQPFPQPELPYPQPQS 18(7)
87(7) 100 PQLPYPQPELPYPQPQP 14(4) 80(17) 69(20) *sequence refers
that of transglutaminase (tTG) modified peptide and the T cell
epitope. Wild type is the unmodified gliadin peptide. Data from 4
subjects. Blank was 5(1)%.
[0239] TABLE-US-00008 TABLE 7 Polymorphisms of A-gliadin 57-73
Alpha-gliadin protein (single letter code refers to FIG. 14
peptides) Polymorphism A. Sequences derived from Nordic autumn
wheat strain Mjoelner Q41545 A-gliadin (from se- QLQPFPQPQLPYPQPQS
quenced protein) 57-73 (A) Gli alpha 1,6: (EMBL: AJ133605
QPQPFPPPQLPYPQTQP & AJ133602 58-74) (J) Gli alpha 3,4,5: (EMBL:
QLQPFPQPQLSYSQPQP AJ133606, AJ133607, AJ133608 57-73) (I) Gli alpha
7: (EMBL: AJ133604 QLQPFPRPQLPYPQPQP 57-73) (E) Gli alpha 8, 9, 11:
(EMBL:) (F) QLQPFPQPQLPYSQPQP Gli alpha 10: (EMBL: AJ133610
QLQPFPQPQLPYLQPQS 57-73) (D) Wheat (Triticum aestivum unless
stated) gliadin accession number Polymorphism B. SWISSPROT and
TREMBL scan (10.12.99) for gliadins containing the sequence:
XXXXXXXPQLPYXXXXX Q41545 A-gliadin (from QLQPFPQPQLPYPQPQS
sequenced protein) 57-73 (A) SWISSPROT: GDAO_WHEAT P02863 77-93 (F)
QLQPFPQPQLPYSQPQP GDA1_WHEAT P04721 77-93 (G) QLQPFLQPQLPSQPQP
GDA2_WHEAT P04722 77-93 (B) QLQPFPQPQLPYPQPQP GDA3_WHEAT P04723
77-93 (O) PQPQPFPPQLPYPQTQP GDA4_WHEAT P04724 77-93 (C)
QLQPFPQPQLPYPQPQL GDA4_WHEAT P04724 84-100 (K) PQLPYPQPQLPYPQPQP
GDA5_WHEAT P04725 82-98 (N) PQPQPFPPQLPYPQPQS GDA6_WHEAT P04726
82-98 (P) PQPQPFPPQLPYPQPPP GDA7_WHEAT P04727 79-95 (M)
PQPOPFLPQLPYPQPQS GDA9_WHEAT P18573 77-93 (C) QLQPFPQPQLPYPQPQL
GDA9_WHEAT P18573 84-100 (L) PQLPYPQPQLPYPQPQL GDA9_WHEAT P18573
91-107 (K) PQLPYPQPQLPYPQPQP TREMBL Q41509 ALPHA-GLIADIN 77-93 (G)
QLQPFLQPQLPYSQPQP Q41528 ALPHA-GLIADIN 76-92 (F) QLQPFPQPQLPYSQPQP
Q41529 ALPHA-GLIADIN 79-95 (M) PQPQPFLPQLPYPQPQS Q41530
ALPHA-GLIADIN 77-93 (H) QLQPFSQPQLPYSQPQP Q41531 ALPHA-GLIADIN
77-93 (F) QLQPFPQPQLPYSQPQP Q41533 ALPHA-GLIADIN 57-73 (F)
QLQPFPQPQLPYSQPQP Q41546 ALPHA/BETA-GLIADIN PQPQPFLPQLPYPQPQS 79-95
(M) Q41632 ALPHA/BETA-TYPE GLIADIN. PQPQPFPPQLPYPQPPP Triticum
urartu 82-98 (P) Q9ZPO9 ALPHA-GLIADIN Triticum QLQPFPQPQLPYSQPQP
spelta 77-93 (F)
[0240] TABLE-US-00009 TABLE 8 Bioactivity of substituted variants
of A-gliadin 57-73 QE65 (Subst) compared to unmodified A- gliadin
57-73 QE65 (G) (mean 100%, 95% CI 97-104) and blank (no peptide,
bl) (mean 7.1%, 95% CI: 5.7-8.5) Subst % P vs G Subst % P vs G
Subst % P vs G Subst % P vs G P vs bl Super-agonists F62 71 0.001
H62 47 <0.0001 N66 24 <0.0001 Y61 129 <0.0001 V63 70
<0.0001 G69 47 <0.0001 R64 24 <0.0001 Y70 129 0.0006 S69
70 <0.0001 N63 47 <0.0001 K63 23 <0.0001 Agonists H63 70
<0.0001 H68 47 <0.0001 V65 23 <0.0001 W70 119 0.017 F63 70
0.008 M68 46 <0.0001 H66 23 <0.0001 K57 118 0.02 P70 69
<0.0001 D68 46 <0.0001 H67 22 <0.0001 Y59 117 0.04 T62 69
<0.0001 V69 46 <0.0001 L64 22 <0.0001 A57 116 0.046 L61 69
<0.0001 G63 45 <0.0001 S66 22 <0.0001 S70 116 0.045 S61 69
<0.0001 V64 45 <0.0001 F67 21 <0.0001 K58 114 0.08 T61 69
<0.0001 E61 45 <0.0001 W66 21 <0.0001 W59 110 0.21 T63 69
<0.0001 A69 43 <0.0001 G64 21 <0.0001 A73 109 0.24 M66 68
<0.0001 R62 42 <0.0001 G65 21 <0.0001 I59 108 0.37 T69 67
<0.0001 G68 42 <0.0001 D64 21 <0.0001 G59 108 0.34 K60 66
<0.0001 A64 42 <0.0001 I65 21 <0.0001 A58 108 0.35 S62 66
<0.0001 C65 42 <0.0001 M64 20 <0.0001 <0.0001 W60 105
0.62 M61 66 <0.0001 N67 41 <0.0001 G67 19 <0.0001
<0.0001 A59 104 0.61 P61 65 <0.0001 W63 41 <0.0001 T65 19
<0.0001 0.003 K72 104 0.65 M62 64 <0.0001 F69 41 <0.0001
A66 19 <0.0001 <0.0001 S59 103 0.76 Q61 64 <0.0001 N68 40
<0.0001 I64 19 <0.0001 0.0003 K73 102 0.8 G61 64 <0.0001
V66 40 <0.0001 R63 19 <0.0001 <0.0001 A70 102 0.81 A63 64
<0.0001 H69 40 <0.0001 W67 19 <0.0001 <0.0001 Y60 101
0.96 L62 60 <0.0001 M69 40 <0.0001 K68 18 <0.0001
<0.0001 A72 100 0.94 I68 60 <0.0001 R69 40 <0.0001 H64 18
<0.0001 <0.0001 S63 98 0.67 S67 59 <0.0001 W69 40
<0.0001 W64 18 <0.0001 0.0001 K59 96 0.46 N61 59 <0.0001
Q69 39 <0.0001 Q65 18 <0.0001 0.0002 I60 96 0.5 I69 59
<0.0001 L67 38 <0.0001 F64 16 <0.0001 0.0008 G70 95 0.41
V61 58 <0.0001 K69 38 <0.0001 L65 16 <0.0001 0.0022 D65 95
0.44 D61 58 <0.0001 K62 38 <0.0001 N64 16 <0.0001
<0.0001 E70 93 0.27 E60 57 <0.0001 E67 37 <0.0001 F65 16
<0.0001 0.12 I63 92 0.19 A61 57 <0.0001 L69 37 <0.0001 Q67
15 <0.0001 0.0012 S60 92 0.23 Q62 56 <0.0001 S64 36
<0.0001 M65 14 <0.0001 0.015 P59 88 0.08 F68 56 <0.0001
G62 36 <0.0001 D66 14 <0.0001 0.013 M63 87 0.03 N65 56
<0.0001 E69 36 <0.0001 R67 14 <0.0001 0.002 K71 85 0.047
A62 56 <0.0001 E68 36 <0.0001 Non-agonists V62 84 0.04 A68 53
<0.0001 V67 35 <0.0001 P63 13 <0.0001 0.012 I70 84 0.04
P66 53 <0.0001 D62 35 <0.0001 E64 12 <0.0001 0.053 I61 83
0.01 R61 53 <0.0001 R68 34 <0.0001 W65 11 <0.0001 0.24 V68
82 0.0045 S68 53 <0.0001 Q66 34 <0.0001 Q64 11 <0.0001
0.15 E59 81 0.01 Y63 52 <0.0001 A67 33 <0.0001 G66 11
<0.0001 0.07 Partial agonists N69 51 <0.0001 N62 32
<0.0001 R65 11 <0.0001 0.26 W61 79 0.002 E63 51 <0.0001
F66 31 <0.0001 Y67 10 <0.0001 0.13 A60 78 0.002 T64 51
<0.0001 E62 31 <0.0001 E66 10 <0.0001 0.17 Y62 78 0.006
T67 51 <0.0001 D69 31 <0.0001 K66 10 <0.0001 0.21 G60 77
0.003 Y69 50 <0.0001 D67 30 <0.0001 R66 10 <0.0001 0.23
A71 77 0.003 D63 50 <0.0001 M67 29 <0.0001 K67 10 <0.0001
0.11 W62 76 0.0009 A65 49 <0.0001 Y66 28 <0.0001 P65 8
<0.0001 0.57 Q60 76 0.001 K61 49 <0.0001 I67 28 <0.0001
K64 8 <0.0001 0.82 L63 74 0.0002 I66 49 <0.0001 H65 26
<0.0001 K65 8 <0.0001 0.63 I62 74 0.0005 T68 48 <0.0001
P68 26 <0.0001 Y65 7 <0.0001 0.9 K70 74 0.001 S65 48
<0.0001 Y64 25 <0.0001 H61 72 <0.0001 L68 48 <0.0001
EK65 25 <0.0001 W68 72 <0.0001 Q68 48 <0.0001 T66 25
<0.0001
[0241] TABLE-US-00010 TABLE 9 Antagonism of A-gliadin 57-73 QE65
interferon gamma ELISPOT response by substituted variants of
A-gliadin 57-73 QE65 (Subst) (P is significance level in unpaired
t-test). Agonist activity (% agonist) of peptides compared to
A-gliadin 57-73 QE65 is also shown. % % Subst Inhibit. P agonist.
Subst % Inhibit. P % agonist. Agonists 65R 13 0.18 11 65T 28 0.004
19 65M 13 0.16 14 67M 27 0.0052 29 68P 13 0.16 26 64W 26 0.007 18
63R 13 0.19 19 67W 25 0.0088 19 66G 12 0.19 11 Potential
antagonists 65Q 12 0.2 18 67I 24 0.13 10 65Y 12 0.22 7 67Y 24 0.013
21 66S 12 0.22 22 64G 21 0.03 21 67F 11 0.25 21 64D 21 0.029 16 66R
10 0.29 10 65L 20 0.046 26 67K 10 0.29 10 66N 20 0.037 24 64F 10
0.29 16 65H 20 0.038 16 65F 9 0.41 16 64N 19 0.05 16 63P 8 0.42 13
64Y 19 0.06 25 65EK 8 0.39 25 66Y 19 0.048 28 64Q 7 0.49 11 64E 19
0.49 12 64I 5 0.6 21 67A 18 0.058 30 68K 5 0.56 19 67H 18 0.052 22
67Q 5 0.61 18 Non-antagonists 65G 5 0.62 15 65V 17 0.07 23 64M 4
0.7 20 65I 17 0.086 21 66H 4 0.66 23 66T 17 0.069 25 66 E 3 0.76 10
65W 15 0.11 11 66D 1 0.9 14 67R 15 0.13 14 63K 1 0.88 23 65P 15
0.13 8 64H 1 0.93 18 65K 15 0.11 8 66K 0 0.98 10 66W 15 0.12 21 64K
-2 0.88 8 67G 14 0.14 19 64L -11 0.26 22 66A 14 0.14 19
[0242] TABLE-US-00011 TABLE 10 Inhibition of A-gliadin 57-73 QE65
interferon gamma ELISPOT response by peptides known to bind HLA-DQ2
(P is significance level in upaired t-test). Peptide % Inhibit. P
TP 31 <0.0001 HLA1a 0 0.95
[0243] TABLE-US-00012 TABLE 11 Antagonism of A-gliadin 57-73 QE65
interferon gamma ELISpot response by naturally occurring
polymorphisms of A-gliadin 57-73 QE65 (P is significance level in
unpaired t-test). % In- hib- A-gliadin 57-73 QE65 polymorphism it.
P P04725 82-98 QE90 PQPOPFPPELPYPQPQS 19 0.009 Q41509 77-93 QE85
QLQPFLQPELPYSQPQP 11 0.15 Gli.alpha. 1,6 58-74 QE66
QPQPFPPPELPYPQTQP 11 0.11 P04723 77-93 QE85 PQPQPFPPELPYPQTQP 10
0.14 Gli.alpha. 3-5 57-73 QE65 QLQPFPQPELSYSQPQP 7 0.34 P02863
77-93 QE85 QLQPFPQPELPYSQPQP 6 0.35 Q41509 77-93 QE85
QLQPFLQPELPYSQPQP 6 0.41 P04727 79-95 QE65 PQPQPFLPELPYPQPQS 6 0.39
P04726 82-98 QE9O PQPQPFPPELPYPQPPP 5 0.43
[0244]
Sequence CWU 1
1
78 1 7 PRT Homo sapiens 1 Pro Gln Pro Glu Leu Pro Tyr 1 5 2 17 PRT
Homo sapiens 2 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro
Gln Pro Gln 1 5 10 15 Ser 3 266 PRT Unknown A-gliadin sequence 3
Val Arg Val Pro Val Pro Gln Leu Gln Pro Gln Asn Pro Ser Gln Gln 1 5
10 15 Gln Pro Gln Glu Gln Val Pro Leu Val Gln Gln Gln Gln Phe Pro
Gly 20 25 30 Gln Gln Gln Gln Phe Pro Pro Gln Gln Pro Tyr Pro Gln
Pro Gln Pro 35 40 45 Phe Pro Ser Gln Gln Pro Tyr Leu Gln Leu Gln
Pro Phe Pro Gln Pro 50 55 60 Gln Leu Pro Tyr Pro Gln Pro Gln Ser
Phe Pro Pro Gln Gln Pro Tyr 65 70 75 80 Pro Gln Pro Gln Pro Gln Tyr
Ser Gln Pro Gln Gln Pro Ile Ser Gln 85 90 95 Gln Gln Ala Gln Gln
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 100 105 110 Gln Ile Leu
Gln Gln Ile Leu Gln Gln Gln Leu Ile Pro Cys Met Asp 115 120 125 Val
Val Leu Gln Gln His Asn Ile Ala His Ala Arg Ser Gln Val Leu 130 135
140 Gln Gln Ser Thr Tyr Gln Leu Leu Gln tlu Leu Cys Cys Gln His Leu
145 150 155 160 Trp Gln Ile Pro Glu Gln Ser Gln Cys Gln Ala Ile His
Asn Val Val 165 170 175 His Ala Ile Ile Leu His Gln Gln Gln Lys Gln
Gln Gln Gln Pro Ser 180 185 190 Ser Gln Val Ser Phe Gln Gln Pro Leu
Gln Gln Tyr Pro Leu Gly Gln 195 200 205 Gly Ser Phe Arg Pro Ser Gln
Gln Asn Pro Gln Ala Gln Gly Ser Val 210 215 220 Gln Pro Gln Gln Leu
Pro Gln Phe Glu Glu Ile Arg Asn Leu Ala Leu 225 230 235 240 Gln Thr
Leu Pro Ala Met Cys Asn Val Tyr Ile Ala Pro Tyr Cys Thr 245 250 255
Ile Ala Pro Phe Gly Ile Phe Gly Thr Asn 260 265 4 5 PRT Homo
sapiens 4 Pro Gln Leu Pro Tyr 1 5 5 5 PRT Homo sapiens 5 Gln Pro
Gln Leu Pro 1 5 6 7 PRT Homo sapiens 6 Pro Gln Pro Gln Leu Pro Tyr
1 5 7 20 PRT Homo sapiens 7 Leu Gln Leu Gln Pro Phe Pro Gln Pro Gln
Leu Pro Tyr Pro Gln Pro 1 5 10 15 Gln Ser Phe Pro 20 8 20 PRT Homo
sapiens 8 Leu Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro
Gln Pro 1 5 10 15 Gln Ser Phe Pro 20 9 17 PRT Homo sapiens 9 Gln
Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10
15 Ser 10 17 PRT Homo sapiens 10 Gln Leu Gln Pro Phe Pro Gln Pro
Glu Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 11 17 PRT Homo
sapiens 11 Pro Gln Pro Gln Pro Phe Pro Pro Glu Leu Pro Tyr Pro Gln
Pro Gln 1 5 10 15 Ser 12 17 PRT Homo sapiens 12 Gln Leu Gln Pro Phe
Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Glu 1 5 10 15 Ser 13 17 PRT
Homo sapiens 13 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro
Gln Pro Glu 1 5 10 15 Ser 14 17 PRT Homo sapiens 14 Glu Leu Gln Pro
Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Glu 1 5 10 15 Ser 15 17
PRT Homo sapiens 15 Gln Pro Gln Pro Phe Pro Pro Pro Gln Leu Pro Tyr
Pro Gln Thr Gln 1 5 10 15 Pro 16 17 PRT Homo sapiens 16 Gln Leu Gln
Pro Phe Pro Gln Pro Gln Leu Ser Tyr Ser Gln Pro Gln 1 5 10 15 Pro
17 17 PRT Homo sapiens 17 Gln Leu Gln Pro Phe Pro Arg Pro Gln Leu
Pro Tyr Pro Gln Pro Gln 1 5 10 15 Pro 18 17 PRT Homo sapiens 18 Gln
Leu Gln tro Phe Pro Gln Pro Gln Leu Pro Tyr Ser Gln Pro Gln 1 5 10
15 Pro 19 17 PRT Homo sapiens 19 Gln Leu Gln Pro Phe Pro Gln Pro
Gln Leu Pro Tyr Leu Gln Pro Gln 1 5 10 15 Ser 20 17 PRT Homo
sapiens 20 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Ser Gln
Pro Gln 1 5 10 15 Pro 21 17 PRT Homo sapiens 21 Gln Leu Gln Pro Phe
Leu Gln Pro Gln Leu Pro Tyr Ser Gln Pro Gln 1 5 10 15 Pro 22 17 PRT
Homo sapiens 22 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro
Gln Pro Gln 1 5 10 15 Pro 23 17 PRT Homo sapiens 23 Pro Gln Pro Gln
Pro Phe Pro Pro Gln Leu Pro Tyr Pro Gln Thr Gln 1 5 10 15 Pro 24 17
PRT Homo sapiens 24 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr
Pro Gln Pro Gln 1 5 10 15 Leu 25 17 PRT Homo sapiens 25 Pro Gln Leu
Pro Tyr Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Pro
26 17 PRT Homo sapiens 26 Pro Gln Pro Gln Pro Phe Pro Pro Gln Leu
Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 27 17 PRT Homo sapiens 27 Pro
Gln Pro Gln Pro Phe Pro Pro Gln Leu Pro Tyr Pro Gln Pro Pro 1 5 10
15 Pro 28 17 PRT Homo sapiens 28 Pro Gln Pro Gln Pro Phe Leu Pro
Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 29 17 PRT Homo
sapiens 29 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln
Pro Gln 1 5 10 15 Leu 30 17 PRT Homo sapiens 30 Pro Gln Leu Pro Tyr
Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Leu 31 17 PRT
Homo sapiens 31 Pro Gln Leu Pro Tyr Pro Gln Pro Gln Leu Pro Tyr Pro
Gln Pro Gln 1 5 10 15 Pro 32 17 PRT Homo sapiens 32 Gln Leu Gln Pro
Phe Leu Gln Pro Gln Leu Pro Tyr Ser Gln Pro Gln 1 5 10 15 Pro 33 17
PRT Homo sapiens 33 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr
Ser Gln Pro Gln 1 5 10 15 Pro 34 17 PRT Homo sapiens 34 Pro Gln Pro
Gln Pro Phe Leu Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser
35 17 PRT Homo sapiens 35 Gln LeutGln Pro Phe Ser Gln Pro Gln Leu
Pro Tyr Ser Gln Pro Gln 1 5 10 15 Pro 36 17 PRT Homo sapiens 36 Gln
Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Ser Gln Pro Gln 1 5 10
15 Pro 37 17 PRT Homo sapiens 37 Gln Leu Gln Pro Phe Pro Gln Pro
Gln Leu Pro Tyr Ser Gln Pro Gln 1 5 10 15 Pro 38 17 PRT Homo
sapiens 38 Pro Gln Pro Gln Pro Phe Leu Pro Gln Leu Pro Tyr Pro Gln
Pro Gln 1 5 10 15 Ser 39 17 PRT Homo sapiens 39 Pro Gln Pro Gln Pro
Phe Pro Pro Gln Leu Pro Tyr Pro Gln Pro Pro 1 5 10 15 Pro 40 17 PRT
Homo sapiens 40 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Ser
Gln Pro Gln 1 5 10 15 Pro 41 17 PRT Homo sapiens 41 Gln Leu Gln Pro
Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Pro 42 17
PRT Homo sapiens 42 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr
Ser Gln Pro Gln 1 5 10 15 Pro 43 17 PRT Homo sapiens 43 Gln Leu Gln
Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Leu
44 17 PRT Homo sapiens 44 Gln Leu Gln Pro Phe Leu Gln Pro Gln Leu
Pro Tyr Ser Gln Pro Gln 1 5 10 15 Pro 45 17 PRT Homo sapiens 45 Gln
Leu Gln Pro Phe Ser Gln Pro Gln Leu Pro Tyr Ser Gln Pro Gln 1 5 10
15 Pro 46 17 PRT Homo sapiens 46 Pro Gln Pro Gln Pro Phe Pro Pro
Gln Leu Pro Tyr Pro Gln Thr Gln 1 5 10 15 Pro 47 17 PRT Homo
sapiens 47 Pro Gln Pro Gln Pro Phe Leu Pro Gln Leu Pro Tyr Pro Gln
Pro Gln 1 5 10 15 Ser 48 17 PRT Homo sapiens 48 Pro Gln Pro Gln Pro
Phe Pro Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 49 17 PRT
Homo sapiens 49 Pro Gln Pro Gln Pro Phe Pro Pro Gln Leu Pro Tyr Pro
Gln Pro Gln 1 5 10 15 Pro 50 17 PRT Homo sapiens 50 Pro Gln Leu Pro
Tyr Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Pro 51 17
PRT Homo sapiens 51 Pro Gln Leu Pro Tyr Pro Gln Pro Gln Leu Pro Tyr
Pro Gln Pro Gln 1 5 10 15 Leu 52 20 PRT Homo sapiens 52 Gln Gln Leu
Pro Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln 1 5 10 15 Glu
Arg Pro Phe 20 53 12 PRT Homo sapiens 53 Gln Leu Gln Pro Phe Pro
Gln Pro Glu Leu Pro Tyr 1 5 10 54 14 PRT Homo sapiens 54 Pro Gln
Pro Glu Leu Pro Tyr Pro Gln Pro Glu Leu Pro Tyr 1 5 10 55 19 PRT
Homo sapiens 55 Leu Gly Gln Gln Gln Pro Phe Pro Pro Gln Gln Pro Tyr
Pro Gln Pro 1 5 10 15 Gln Pro Phe 56 18 PRT Homo sapiens 56 Gln Gln
Tyr Pro Ser Gly Glu Gly Ser Phe Gln Pro Ser Gln Glu Asn 1 5 10 15
Pro Gln 57 15 PRT Homo sapiens 57 Gly Gln Gln Gly Tyr Tyr Pro Thr
Ser Pro Gln Gln Ser Gly Gln 1 5 10 15 58 17 PRT Homo sapiens 58 Gln
Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Gln 1 5 10
15 Ser 59 17 PRT Homo sapiens 59 Pro Gln Leu Pro Tyr Pro Gln Pro
Glu Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Pro 60 11 PRT Homo
sapiens 60 Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln 1 5 10 61 14
PRT Homo sapiens 61 Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu
Tyr Trp 1 5 10 62 16 PRT Homo sapiens 62 Ile Asp Val Trp Leu Gly
Gly Leu Leu Ala Glu Asn Phe Leu Pro Tyr 1 5 10 15 63 12 PRT Homo
sapiens 63 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr 1 5 10
64 17 PRT Homo sapiens 64 Pro Gln Pro Gln Pro Phe Pro Pro Glu Leu
Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 65 17 PRT Homo sapiens 65 Gln
Leu Gln Pro Phe Leu Gln Pro Glu Leu Pro Tyr Ser Gln Pro Gln 1 5 10
15 Pro 66 17 PRT Homo sapiens 66 Gln Pro Gln Pro Phe Pro Pro Pro
Glu Leu Pro Tyr Pro Gln Thr Gln 1 5 10 15 Pro 67 17 PRT Homo
sapiens 67 Pro Gln Pro Gln Pro Phe Pro Pro Glu Leu Pro Tyr Pro Gln
Thr Gln 1 5 10 15 Pro 68 17 PRT Homo sapiens 68 Gln Leu Gln Pro Phe
Pro Gln Pro Glu Leu Ser Tyr Ser Gln Pro Gln 1 5 10 15 Pro 69 17 PRT
Homo sapiens 69 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Ser
Gln Pro Gln 1 5 10 15 Pro 70 17 PRT Homo sapiens 70 Pro Gln Pro Gln
Pro Phe Pro Pro Glu Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 71 17
PRT Homo sapiens 71 Gln Leu Gln Pro Phe Leu Gln Pro Glu Leu Pro Tyr
Ser Gln Pro Gln 1 5 10 15 Pro 72 17 PRT Homo sapiens 72 Gln Pro Gln
Pro Phe Pro Pro Pro Glu Leu Pro Tyr Pro Gln Thr Gln 1 5 10 15 Pro
73 17 PRT Homo sapiens 73 Pro Gln Pro Gln Pro Phe Pro Pro Glu Leu
Pro Tyr Pro Gln Thr Gln 1 5 10 15 Pro 74 17 PRT Homo sapiens 74 Gln
Leu Gln Pro Phe Pro Gln Pro Glu Leu Ser Tyr Ser Gln Pro Gln 1 5 10
15 Pro 75 17 PRT Homo sapiens 75 Gln Leu Gln Pro Phe Pro Gln Pro
Glu Leu Pro Tyr Ser Gln Pro Gln 1 5 10 15 Pro 76 17 PRT Homo
sapiens 76 Gln Leu Gln Pro Phe Leu Gln Pro Glu Leu Pro Tyr Ser Gln
Pro Gln 1 5 10 15 Pro 77 17 PRT Homo sapiens 77 Pro Gln Pro Gln Pro
Phe Leu Pro Glu Leu Pro Tyr Pro Gln Pro Gln 1 5 10 15 Ser 78 17 PRT
Homo sapiens 78 Pro Gln Pro Gln Pro Phe Pro Pro Glu Leu Pro Tyr Pro
Gln Pro Pro 1 5 10 15 Pro
* * * * *
References